drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.69k
| drug2_id
int64 0
1.69k
| drug_pair
listlengths 2
2
| drug1_name
stringlengths 4
85
| drug2_name
stringlengths 4
85
| drug1_desc
stringlengths 27
1.09k
| drug2_desc
stringlengths 27
6.14k
| label
stringclasses 3
values | label_idx
int64 0
2
| all_paths
listlengths 1
10
| all_paths_str
listlengths 1
10
| path_str
stringlengths 0
3.57k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00705
|
DB11967
| 441
| 710
|
[
"DDInter496",
"DDInter210"
] |
Delavirdine
|
Binimetinib
|
A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
|
Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.
|
Moderate
| 1
|
[
[
[
441,
24,
710
]
],
[
[
441,
25,
1593
],
[
1593,
24,
710
]
],
[
[
441,
64,
1557
],
[
1557,
24,
710
]
],
[
[
441,
63,
883
],
[
883,
24,
710
]
],
[
[
441,
24,
1619
],
[
1619,
63,
710
]
],
[
[
441,
23,
466
],
[
466,
63,
710
]
],
[
[
441,
24,
1220
],
[
1220,
24,
710
]
],
[
[
441,
23,
1374
],
[
1374,
24,
710
]
],
[
[
441,
25,
214
],
[
214,
63,
710
]
],
[
[
441,
25,
405
],
[
405,
25,
710
]
]
] |
[
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Astemizole"
],
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Delavirdine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Delavirdine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Binimetinib"
]
]
] |
Delavirdine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Delavirdine may lead to a major life threatening interaction when taken with Astemizole and Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Delavirdine may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Delavirdine may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Delavirdine may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Delavirdine may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may lead to a major life threatening interaction when taken with Binimetinib
|
DB00515
|
DB01165
| 589
| 1,539
|
[
"DDInter387",
"DDInter1325"
] |
Cisplatin
|
Ofloxacin
|
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
|
A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
|
Minor
| 0
|
[
[
[
589,
23,
1539
]
],
[
[
589,
62,
1467
],
[
1467,
1,
1539
]
],
[
[
589,
23,
945
],
[
945,
40,
1539
]
],
[
[
589,
23,
739
],
[
739,
1,
1539
]
],
[
[
589,
6,
5912
],
[
5912,
45,
1539
]
],
[
[
589,
21,
28963
],
[
28963,
60,
1539
]
],
[
[
589,
24,
1238
],
[
1238,
23,
1539
]
],
[
[
589,
64,
1648
],
[
1648,
23,
1539
]
],
[
[
589,
63,
141
],
[
141,
23,
1539
]
],
[
[
589,
24,
1532
],
[
1532,
62,
1539
]
]
] |
[
[
[
"Cisplatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
]
],
[
[
"Cisplatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enoxacin"
],
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
]
],
[
[
"Cisplatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
]
],
[
[
"Cisplatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
]
],
[
[
"Cisplatin",
"{u} (Compound) binds {v} (Gene)",
"ABCC2"
],
[
"ABCC2",
"{u} (Gene) is bound by {v} (Compound)",
"Ofloxacin"
]
],
[
[
"Cisplatin",
"{u} (Compound) causes {v} (Side Effect)",
"Anxiety"
],
[
"Anxiety",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ofloxacin"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
],
[
"Pentostatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Floxuridine"
],
[
"Floxuridine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
]
]
] |
Cisplatin may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Ofloxacin (Compound)
Cisplatin may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Ofloxacin (Compound)
Cisplatin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Ofloxacin (Compound)
Cisplatin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Ofloxacin (Compound)
Cisplatin (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Ofloxacin (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin and Pentostatin may cause a minor interaction that can limit clinical effects when taken with Ofloxacin
Cisplatin may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Ofloxacin
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a minor interaction that can limit clinical effects when taken with Ofloxacin
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a minor interaction that can limit clinical effects when taken with Ofloxacin
|
DB01069
|
DB14881
| 401
| 180
|
[
"DDInter1533",
"DDInter1329"
] |
Promethazine
|
Oliceridine
|
Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000]
|
Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of opioid agonists.[A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin, the beneficial analgesic effects of opioids are coupled with severe adverse effects such as constipation and respiratory depression.[A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor phosphorylation and recruitment of β-arrestin.[A218026, A218031] By acting as a biased agonist, oliceridine provides comparable analgesia compared with traditional opioids such as [morphine] at a comparable or decreased risk of opioid-related adverse effects such as constipation and respiratory depression.[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by the Anesthetic and Analgesic Drug Products Advisory Committee. Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™.
|
Moderate
| 1
|
[
[
[
401,
24,
180
]
],
[
[
401,
62,
112
],
[
112,
23,
180
]
],
[
[
401,
24,
1637
],
[
1637,
24,
180
]
],
[
[
401,
63,
618
],
[
618,
24,
180
]
],
[
[
401,
23,
286
],
[
286,
24,
180
]
],
[
[
401,
25,
1311
],
[
1311,
24,
180
]
],
[
[
401,
64,
702
],
[
702,
25,
180
]
],
[
[
401,
25,
1154
],
[
1154,
25,
180
]
],
[
[
401,
24,
760
],
[
760,
25,
180
]
],
[
[
401,
63,
1133
],
[
1133,
25,
180
]
]
] |
[
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oliceridine"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
],
[
"Amyl Nitrite",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abarelix"
],
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
]
] |
Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Promethazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Promethazine may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Oliceridine
Promethazine may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Oliceridine
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Oliceridine
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may lead to a major life threatening interaction when taken with Oliceridine
|
DB06210
|
DB09054
| 72
| 384
|
[
"DDInter631",
"DDInter905"
] |
Eltrombopag
|
Idelalisib
|
Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
|
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
|
Moderate
| 1
|
[
[
[
72,
24,
384
]
],
[
[
72,
24,
1627
],
[
1627,
62,
384
]
],
[
[
72,
63,
289
],
[
289,
24,
384
]
],
[
[
72,
24,
788
],
[
788,
24,
384
]
],
[
[
72,
24,
242
],
[
242,
63,
384
]
],
[
[
72,
64,
491
],
[
491,
24,
384
]
],
[
[
72,
25,
412
],
[
412,
63,
384
]
],
[
[
72,
23,
74
],
[
74,
24,
384
]
],
[
[
72,
25,
350
],
[
350,
24,
384
]
],
[
[
72,
63,
392
],
[
392,
25,
384
]
]
] |
[
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cerivastatin"
],
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Eltrombopag",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Eltrombopag",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eluxadoline"
],
[
"Eluxadoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Eltrombopag",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Boceprevir"
],
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Eltrombopag",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
]
] |
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin and Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Eltrombopag may lead to a major life threatening interaction when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Eltrombopag may lead to a major life threatening interaction when taken with Eluxadoline and Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Eltrombopag may cause a minor interaction that can limit clinical effects when taken with Boceprevir and Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Eltrombopag may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Idelalisib
|
DB01175
|
DB01611
| 318
| 1,487
|
[
"DDInter672",
"DDInter893"
] |
Escitalopram
|
Hydroxychloroquine
|
Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from
|
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of [quinacrine] with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2. **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.** Hydroxychloroquine was granted FDA approval on 18 April 1955. A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.
|
Major
| 2
|
[
[
[
318,
25,
1487
]
],
[
[
318,
64,
1520
],
[
1520,
25,
1487
]
],
[
[
318,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
318,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
318,
62,
723
],
[
723,
24,
1487
]
],
[
[
318,
63,
245
],
[
245,
24,
1487
]
],
[
[
318,
24,
286
],
[
286,
63,
1487
]
],
[
[
318,
64,
521
],
[
521,
24,
1487
]
],
[
[
318,
25,
129
],
[
129,
63,
1487
]
],
[
[
318,
23,
760
],
[
760,
63,
1487
]
]
] |
[
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primaquine"
],
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Escitalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Hydroxychloroquine"
]
],
[
[
"Escitalopram",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydroxychloroquine"
]
],
[
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
]
] |
Escitalopram may lead to a major life threatening interaction when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Escitalopram (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Escitalopram (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Escitalopram may lead to a major life threatening interaction when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Escitalopram may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
|
DB00424
|
DB00761
| 19
| 1,621
|
[
"DDInter896",
"DDInter1497"
] |
Hyoscyamine
|
Potassium chloride
|
Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimuscarinic properties.[L31548,L31553] Although hyoscyamine is marketed in the United States, it is not FDA approved.[L31548,L31553]
|
A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium per dosage unit, except for controlled-release dosage forms and those products formulated for preparation of solution prior to ingestion.
|
Major
| 2
|
[
[
[
19,
25,
1621
]
],
[
[
19,
21,
28809
],
[
28809,
60,
1621
]
],
[
[
19,
63,
1105
],
[
1105,
25,
1621
]
],
[
[
19,
24,
667
],
[
667,
64,
1621
]
],
[
[
19,
24,
13
],
[
13,
25,
1621
]
],
[
[
19,
74,
357
],
[
357,
25,
1621
]
],
[
[
19,
21,
28809
],
[
28809,
60,
803
],
[
803,
1,
1621
]
],
[
[
19,
21,
29063
],
[
29063,
60,
831
],
[
831,
24,
1621
]
],
[
[
19,
21,
29263
],
[
29263,
60,
85
],
[
85,
25,
1621
]
],
[
[
19,
21,
30152
],
[
30152,
60,
413
],
[
413,
64,
1621
]
]
] |
[
[
[
"Hyoscyamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
]
],
[
[
"Hyoscyamine",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Potassium chloride"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trihexyphenidyl"
],
[
"Trihexyphenidyl",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
],
[
"Solifenacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
]
],
[
[
"Hyoscyamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzatropine"
],
[
"Benzatropine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
]
],
[
[
"Hyoscyamine",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Calcium chloride"
],
[
"Calcium chloride",
"{u} (Compound) resembles {v} (Compound)",
"Potassium chloride"
]
],
[
[
"Hyoscyamine",
"{u} (Compound) causes {v} (Side Effect)",
"Dysarthria"
],
[
"Dysarthria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Indomethacin"
],
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium chloride"
]
],
[
[
"Hyoscyamine",
"{u} (Compound) causes {v} (Side Effect)",
"Intoxication"
],
[
"Intoxication",
"{u} (Side Effect) is caused by {v} (Compound)",
"Atropine"
],
[
"Atropine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
]
],
[
[
"Hyoscyamine",
"{u} (Compound) causes {v} (Side Effect)",
"Electrocardiogram QRS complex"
],
[
"Electrocardiogram QRS complex",
"{u} (Side Effect) is caused by {v} (Compound)",
"Maprotiline"
],
[
"Maprotiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
]
]
] |
Hyoscyamine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Potassium chloride (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl and Trihexyphenidyl may lead to a major life threatening interaction when taken with Potassium chloride
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin and Solifenacin may lead to a major life threatening interaction when taken with Potassium chloride
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may lead to a major life threatening interaction when taken with Potassium chloride
Hyoscyamine (Compound) resembles Benzatropine (Compound) and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Benzatropine and Benzatropine may lead to a major life threatening interaction when taken with Potassium chloride
Hyoscyamine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Calcium chloride (Compound) and Calcium chloride (Compound) resembles Potassium chloride (Compound)
Hyoscyamine (Compound) causes Dysarthria (Side Effect) and Dysarthria (Side Effect) is caused by Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Potassium chloride
Hyoscyamine (Compound) causes Intoxication (Side Effect) and Intoxication (Side Effect) is caused by Atropine (Compound) and Atropine may lead to a major life threatening interaction when taken with Potassium chloride
Hyoscyamine (Compound) causes Electrocardiogram QRS complex (Side Effect) and Electrocardiogram QRS complex (Side Effect) is caused by Maprotiline (Compound) and Maprotiline may lead to a major life threatening interaction when taken with Potassium chloride
|
DB10343
|
DB14762
| 962
| 994
|
[
"DDInter160",
"DDInter1602"
] |
Bacillus calmette-guerin substrain tice live antigen
|
Risankizumab
|
Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis.
|
Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis.
|
Major
| 2
|
[
[
[
962,
25,
994
]
],
[
[
962,
64,
4
],
[
4,
24,
994
]
],
[
[
962,
25,
270
],
[
270,
24,
994
]
],
[
[
962,
25,
676
],
[
676,
64,
994
]
],
[
[
962,
64,
1510
],
[
1510,
25,
994
]
],
[
[
962,
25,
1259
],
[
1259,
25,
994
]
],
[
[
962,
64,
4
],
[
4,
63,
58
],
[
58,
24,
994
]
],
[
[
962,
64,
58
],
[
58,
23,
1114
],
[
1114,
23,
994
]
],
[
[
962,
25,
270
],
[
270,
62,
1114
],
[
1114,
23,
994
]
],
[
[
962,
64,
147
],
[
147,
63,
1461
],
[
1461,
23,
994
]
]
] |
[
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risankizumab"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risankizumab"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risankizumab"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risankizumab"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risankizumab"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risankizumab"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risankizumab"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Risankizumab"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Risankizumab"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Risankizumab"
]
]
] |
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Risankizumab
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Risankizumab
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Risankizumab
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Alefacept and Alefacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Risankizumab
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Risankizumab
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Risankizumab
|
DB01156
|
DB06209
| 593
| 256
|
[
"DDInter252",
"DDInter1508"
] |
Bupropion
|
Prasugrel
|
Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810] Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MA
|
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
|
Minor
| 0
|
[
[
[
593,
23,
256
]
],
[
[
593,
6,
8374
],
[
8374,
45,
256
]
],
[
[
593,
21,
28681
],
[
28681,
60,
256
]
],
[
[
593,
62,
752
],
[
752,
23,
256
]
],
[
[
593,
64,
1161
],
[
1161,
23,
256
]
],
[
[
593,
63,
188
],
[
188,
23,
256
]
],
[
[
593,
25,
901
],
[
901,
24,
256
]
],
[
[
593,
64,
421
],
[
421,
24,
256
]
],
[
[
593,
25,
1427
],
[
1427,
63,
256
]
],
[
[
593,
63,
305
],
[
305,
24,
256
]
]
] |
[
[
[
"Bupropion",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Bupropion",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Prasugrel"
]
],
[
[
"Bupropion",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Prasugrel"
]
],
[
[
"Bupropion",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Selegiline"
],
[
"Selegiline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydromorphone"
],
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vortioxetine"
],
[
"Vortioxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
]
] |
Bupropion (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Prasugrel (Compound)
Bupropion (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Bupropion may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Bupropion may lead to a major life threatening interaction when taken with Selegiline and Selegiline may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Nevirapine and Nevirapine may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Bupropion may lead to a major life threatening interaction when taken with Milnacipran and Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Bupropion may lead to a major life threatening interaction when taken with Hydromorphone and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Bupropion may lead to a major life threatening interaction when taken with Vortioxetine and Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
|
DB00277
|
DB00951
| 1,031
| 1,072
|
[
"DDInter1791",
"DDInter986"
] |
Theophylline
|
Isoniazid
|
A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD.
|
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
|
Moderate
| 1
|
[
[
[
1031,
24,
1072
]
],
[
[
1031,
6,
8374
],
[
8374,
45,
1072
]
],
[
[
1031,
21,
28722
],
[
28722,
60,
1072
]
],
[
[
1031,
24,
1486
],
[
1486,
62,
1072
]
],
[
[
1031,
24,
870
],
[
870,
23,
1072
]
],
[
[
1031,
23,
417
],
[
417,
23,
1072
]
],
[
[
1031,
63,
912
],
[
912,
24,
1072
]
],
[
[
1031,
24,
617
],
[
617,
63,
1072
]
],
[
[
1031,
24,
663
],
[
663,
24,
1072
]
],
[
[
1031,
24,
1510
],
[
1510,
64,
1072
]
]
] |
[
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
]
],
[
[
"Theophylline",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Isoniazid"
]
],
[
[
"Theophylline",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Isoniazid"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isoniazid"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isoniazid"
]
],
[
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isoniazid"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoniazid"
]
]
] |
Theophylline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Isoniazid (Compound)
Theophylline (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Isoniazid (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Isoniazid
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Isoniazid
Theophylline may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Isoniazid
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Isoniazid
|
DB00307
|
DB01072
| 1,101
| 915
|
[
"DDInter202",
"DDInter129"
] |
Bexarotene
|
Atazanavir
|
Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
|
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.
|
Moderate
| 1
|
[
[
[
1101,
24,
915
]
],
[
[
1101,
24,
1327
],
[
1327,
1,
915
]
],
[
[
1101,
6,
6017
],
[
6017,
45,
915
]
],
[
[
1101,
21,
28660
],
[
28660,
60,
915
]
],
[
[
1101,
25,
5
],
[
5,
63,
915
]
],
[
[
1101,
62,
168
],
[
168,
24,
915
]
],
[
[
1101,
24,
1195
],
[
1195,
24,
915
]
],
[
[
1101,
63,
1685
],
[
1685,
24,
915
]
],
[
[
1101,
24,
129
],
[
129,
63,
915
]
],
[
[
1101,
23,
1051
],
[
1051,
24,
915
]
]
] |
[
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} (Compound) resembles {v} (Compound)",
"Atazanavir"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Atazanavir"
]
],
[
[
"Bexarotene",
"{u} (Compound) causes {v} (Side Effect)",
"Pelvic pain"
],
[
"Pelvic pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Atazanavir"
]
],
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Liraglutide"
],
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
]
] |
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) resembles Atazanavir (Compound)
Bexarotene (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Atazanavir (Compound)
Bexarotene (Compound) causes Pelvic pain (Side Effect) and Pelvic pain (Side Effect) is caused by Atazanavir (Compound)
Bexarotene may lead to a major life threatening interaction when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir
|
DB00372
|
DB00780
| 999
| 551
|
[
"DDInter1793",
"DDInter1440"
] |
Thiethylperazine
|
Phenelzine
|
A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457)
|
Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.
|
Moderate
| 1
|
[
[
[
999,
24,
551
]
],
[
[
999,
24,
1161
],
[
1161,
40,
551
]
],
[
[
999,
63,
73
],
[
73,
25,
551
]
],
[
[
999,
63,
80
],
[
80,
40,
551
]
],
[
[
999,
24,
1442
],
[
1442,
23,
551
]
],
[
[
999,
24,
1192
],
[
1192,
62,
551
]
],
[
[
999,
24,
473
],
[
473,
63,
551
]
],
[
[
999,
24,
128
],
[
128,
24,
551
]
],
[
[
999,
63,
245
],
[
245,
24,
551
]
],
[
[
999,
25,
1311
],
[
1311,
63,
551
]
]
] |
[
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
],
[
"Selegiline",
"{u} (Compound) resembles {v} (Compound)",
"Phenelzine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenelzine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphetamine"
],
[
"Amphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Phenelzine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
],
[
"Scopolamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenelzine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenelzine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
]
]
] |
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Selegiline and Selegiline (Compound) resembles Phenelzine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Phenelzine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Phenelzine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine may cause a minor interaction that can limit clinical effects when taken with Phenelzine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a minor interaction that can limit clinical effects when taken with Phenelzine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine
Thiethylperazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine
|
DB00486
|
DB01197
| 1,614
| 1,603
|
[
"DDInter1253",
"DDInter292"
] |
Nabilone
|
Captopril
|
Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are
|
Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.
|
Moderate
| 1
|
[
[
[
1614,
24,
1603
]
],
[
[
1614,
24,
610
],
[
610,
1,
1603
]
],
[
[
1614,
21,
28921
],
[
28921,
60,
1603
]
],
[
[
1614,
24,
401
],
[
401,
24,
1603
]
],
[
[
1614,
63,
475
],
[
475,
24,
1603
]
],
[
[
1614,
24,
849
],
[
849,
63,
1603
]
],
[
[
1614,
40,
530
],
[
530,
24,
1603
]
],
[
[
1614,
24,
610
],
[
610,
5,
11576
],
[
11576,
44,
1603
]
],
[
[
1614,
21,
28921
],
[
28921,
60,
610
],
[
610,
1,
1603
]
],
[
[
1614,
21,
29335
],
[
29335,
60,
372
],
[
372,
24,
1603
]
]
] |
[
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Captopril"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Captopril"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Nabilone",
"{u} (Compound) resembles {v} (Compound)",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
"Enalapril",
"{u} (Compound) treats {v} (Disease)",
"coronary artery disease"
],
[
"coronary artery disease",
"{u} (Disease) is treated by {v} (Compound)",
"Captopril"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Enalapril"
],
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Captopril"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotensive"
],
[
"Hypotensive",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
]
] |
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Captopril (Compound)
Nabilone (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Captopril (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Captopril
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Captopril
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Captopril
Nabilone (Compound) resembles Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Captopril
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) treats coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Captopril (Compound)
Nabilone (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Enalapril (Compound) and Enalapril (Compound) resembles Captopril (Compound)
Nabilone (Compound) causes Hypotensive (Side Effect) and Hypotensive (Side Effect) is caused by Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Captopril
|
DB00390
|
DB04843
| 1,252
| 1,511
|
[
"DDInter554",
"DDInter1149"
] |
Digoxin
|
Mepenzolate
|
Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digitalis_ plant, studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.
|
Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ganglionic parasympathetic inhibitor. It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications.
|
Minor
| 0
|
[
[
[
1252,
23,
1511
]
],
[
[
1252,
23,
1192
],
[
1192,
24,
1511
]
],
[
[
1252,
63,
352
],
[
352,
24,
1511
]
],
[
[
1252,
7,
2026
],
[
2026,
46,
1511
]
],
[
[
1252,
18,
4930
],
[
4930,
57,
1511
]
],
[
[
1252,
21,
28722
],
[
28722,
60,
1511
]
],
[
[
1252,
23,
1192
],
[
1192,
63,
675
],
[
675,
24,
1511
]
],
[
[
1252,
23,
262
],
[
262,
74,
675
],
[
675,
24,
1511
]
],
[
[
1252,
63,
352
],
[
352,
24,
675
],
[
675,
24,
1511
]
],
[
[
1252,
7,
2026
],
[
2026,
17,
4930
],
[
4930,
57,
1511
]
]
] |
[
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mepenzolate"
]
],
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Digoxin",
"{u} (Compound) upregulates {v} (Gene)",
"EGR1"
],
[
"EGR1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Mepenzolate"
]
],
[
[
"Digoxin",
"{u} (Compound) downregulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downregulated by {v} (Compound)",
"Mepenzolate"
]
],
[
[
"Digoxin",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mepenzolate"
]
],
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clidinium"
],
[
"Clidinium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Digoxin",
"{u} (Compound) upregulates {v} (Gene)",
"EGR1"
],
[
"EGR1",
"{u} (Gene) regulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downregulated by {v} (Compound)",
"Mepenzolate"
]
]
] |
Digoxin may cause a minor interaction that can limit clinical effects when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Digoxin (Compound) upregulates EGR1 (Gene) and EGR1 (Gene) is upregulated by Mepenzolate (Compound)
Digoxin (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Mepenzolate (Compound)
Digoxin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Mepenzolate (Compound)
Digoxin may cause a minor interaction that can limit clinical effects when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Digoxin may cause a minor interaction that can limit clinical effects when taken with Clidinium and Clidinium (Compound) resembles Dextropropoxyphene (Compound) and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Digoxin (Compound) upregulates EGR1 (Gene) and EGR1 (Gene) regulates DLD (Gene) and DLD (Gene) is downregulated by Mepenzolate (Compound)
|
DB00900
|
DB01083
| 45
| 1,142
|
[
"DDInter544",
"DDInter1348"
] |
Didanosine
|
Orlistat
|
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.
|
The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required. Orlistat is a lipase inhibitor used in the treatment of obesity that works by inhibiting fat-metabolizing enzymes. It was approved by the FDA for use in combination with a reduced-calorie diet in 1999. This drug is a generally well-tolerated and effective weight-loss aid and is now available in both over-the-counter and prescription preparations, depending on the dosage quantity.
|
Moderate
| 1
|
[
[
[
45,
24,
1142
]
],
[
[
45,
21,
28900
],
[
28900,
60,
1142
]
],
[
[
45,
24,
850
],
[
850,
63,
1142
]
],
[
[
45,
63,
372
],
[
372,
24,
1142
]
],
[
[
45,
25,
1510
],
[
1510,
64,
1142
]
],
[
[
45,
21,
28900
],
[
28900,
60,
1477
],
[
1477,
63,
1142
]
],
[
[
45,
21,
28709
],
[
28709,
60,
1331
],
[
1331,
23,
1142
]
],
[
[
45,
21,
28719
],
[
28719,
60,
11753
],
[
11753,
40,
1142
]
],
[
[
45,
21,
29013
],
[
29013,
60,
245
],
[
245,
24,
1142
]
],
[
[
45,
21,
28681
],
[
28681,
60,
11217
],
[
11217,
1,
1142
]
]
] |
[
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Didanosine",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Orlistat"
]
],
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Didanosine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Orlistat"
]
],
[
[
"Didanosine",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Telbivudine"
],
[
"Telbivudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Didanosine",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ergocalciferol"
],
[
"Ergocalciferol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Orlistat"
]
],
[
[
"Didanosine",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ethanolamine Oleate"
],
[
"Ethanolamine Oleate",
"{u} (Compound) resembles {v} (Compound)",
"Orlistat"
]
],
[
[
"Didanosine",
"{u} (Compound) causes {v} (Side Effect)",
"Diabetes mellitus"
],
[
"Diabetes mellitus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Didanosine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sodium Tetradecyl Sulfate"
],
[
"Sodium Tetradecyl Sulfate",
"{u} (Compound) resembles {v} (Compound)",
"Orlistat"
]
]
] |
Didanosine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Orlistat (Compound)
Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Didanosine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Orlistat
Didanosine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Telbivudine (Compound) and Telbivudine may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Didanosine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Ergocalciferol (Compound) and Ergocalciferol may cause a minor interaction that can limit clinical effects when taken with Orlistat
Didanosine (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Ethanolamine Oleate (Compound) and Ethanolamine Oleate (Compound) resembles Orlistat (Compound)
Didanosine (Compound) causes Diabetes mellitus (Side Effect) and Diabetes mellitus (Side Effect) is caused by Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Didanosine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Sodium Tetradecyl Sulfate (Compound) and Sodium Tetradecyl Sulfate (Compound) resembles Orlistat (Compound)
|
DB00692
|
DB00800
| 274
| 572
|
[
"DDInter1448",
"DDInter720"
] |
Phentolamine
|
Fenoldopam
|
Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[A261781, A261786] It has several therapeutic uses, including the treatment of hypertensive episodes, prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue anesthesia, and treatment of pharmacologically-induced mydriasis.[L48420, L48415, L48390] Phentolamine is administered intravenously, intramuscularly, submucosally, and topically.
|
A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
|
Moderate
| 1
|
[
[
[
274,
24,
572
]
],
[
[
274,
10,
11590
],
[
11590,
44,
572
]
],
[
[
274,
6,
5299
],
[
5299,
45,
572
]
],
[
[
274,
21,
29355
],
[
29355,
60,
572
]
],
[
[
274,
63,
999
],
[
999,
24,
572
]
],
[
[
274,
24,
923
],
[
923,
63,
572
]
],
[
[
274,
10,
11590
],
[
11590,
9,
5214
],
[
5214,
45,
572
]
],
[
[
274,
6,
5299
],
[
5299,
45,
1264
],
[
1264,
63,
572
]
],
[
[
274,
6,
5700
],
[
5700,
0,
5214
],
[
5214,
45,
572
]
],
[
[
274,
6,
5214
],
[
5214,
48,
11590
],
[
11590,
44,
572
]
]
] |
[
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenoldopam"
]
],
[
[
"Phentolamine",
"{u} (Compound) palliates {v} (Disease)",
"hypertension"
],
[
"hypertension",
"{u} (Disease) is treated by {v} (Compound)",
"Fenoldopam"
]
],
[
[
"Phentolamine",
"{u} (Compound) binds {v} (Gene)",
"ADRA2C"
],
[
"ADRA2C",
"{u} (Gene) is bound by {v} (Compound)",
"Fenoldopam"
]
],
[
[
"Phentolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Injection site reaction"
],
[
"Injection site reaction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fenoldopam"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenoldopam"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
],
[
"Amifostine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenoldopam"
]
],
[
[
"Phentolamine",
"{u} (Compound) palliates {v} (Disease)",
"hypertension"
],
[
"hypertension",
"{u} (Disease) is associated with {v} (Gene)",
"ADRA1A"
],
[
"ADRA1A",
"{u} (Gene) is bound by {v} (Compound)",
"Fenoldopam"
]
],
[
[
"Phentolamine",
"{u} (Compound) binds {v} (Gene)",
"ADRA2C"
],
[
"ADRA2C",
"{u} (Gene) is bound by {v} (Compound)",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenoldopam"
]
],
[
[
"Phentolamine",
"{u} (Compound) binds {v} (Gene)",
"ADRA1D"
],
[
"ADRA1D",
"{u} (Gene) interacts with {v} (Gene)",
"ADRA1A"
],
[
"ADRA1A",
"{u} (Gene) is bound by {v} (Compound)",
"Fenoldopam"
]
],
[
[
"Phentolamine",
"{u} (Compound) binds {v} (Gene)",
"ADRA1A"
],
[
"ADRA1A",
"{u} (Gene) is associated with {v} (Disease)",
"hypertension"
],
[
"hypertension",
"{u} (Disease) is treated by {v} (Compound)",
"Fenoldopam"
]
]
] |
Phentolamine (Compound) palliates hypertension (Disease) and hypertension (Disease) is treated by Fenoldopam (Compound)
Phentolamine (Compound) binds ADRA2C (Gene) and ADRA2C (Gene) is bound by Fenoldopam (Compound)
Phentolamine (Compound) causes Injection site reaction (Side Effect) and Injection site reaction (Side Effect) is caused by Fenoldopam (Compound)
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Fenoldopam
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Amifostine and Amifostine may cause a moderate interaction that could exacerbate diseases when taken with Fenoldopam
Phentolamine (Compound) palliates hypertension (Disease) and hypertension (Disease) is associated with ADRA1A (Gene) and ADRA1A (Gene) is bound by Fenoldopam (Compound)
Phentolamine (Compound) binds ADRA2C (Gene) and ADRA2C (Gene) is bound by Doxepin (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Fenoldopam
Phentolamine (Compound) binds ADRA1D (Gene) and ADRA1D (Gene) interacts with ADRA1A (Gene) and ADRA1A (Gene) is bound by Fenoldopam (Compound)
Phentolamine (Compound) binds ADRA1A (Gene) and ADRA1A (Gene) is associated with hypertension (Disease) and hypertension (Disease) is treated by Fenoldopam (Compound)
|
DB00196
|
DB11642
| 600
| 938
|
[
"DDInter743",
"DDInter1480"
] |
Fluconazole
|
Pitolisant
|
Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.
|
Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. Histaminergic neuron signalling in the brain plays a role in maintaining wakefulness; by blocking histamine autoreceptors, pitolisant enhances the activity of histaminergic neurons, as well as increasing the signalling of other neurotransmitters in the brain. In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. The therapeutic effectiveness of pitolisant was comparable to that of [modafinil]. Pitolisant therapy was also effective in treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and increased the mean sleep onset latency. Adolescent patients with cataplexy also experienced a slight improvement in the frequency and severity of symptoms ; however, the safety of use in adolescent or paediatric patients have not been established with pitolisant. Commonly marketed under the trade name Wakix, oral pitolisant was approved by the EMA in 2016 for the treatment of narcolepsy with or without cataplexy. FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults.
|
Moderate
| 1
|
[
[
[
600,
24,
938
]
],
[
[
600,
23,
112
],
[
112,
23,
938
]
],
[
[
600,
24,
760
],
[
760,
24,
938
]
],
[
[
600,
25,
1181
],
[
1181,
24,
938
]
],
[
[
600,
23,
1413
],
[
1413,
24,
938
]
],
[
[
600,
25,
927
],
[
927,
63,
938
]
],
[
[
600,
63,
521
],
[
521,
24,
938
]
],
[
[
600,
24,
1499
],
[
1499,
63,
938
]
],
[
[
600,
25,
1154
],
[
1154,
25,
938
]
],
[
[
600,
25,
351
],
[
351,
64,
938
]
]
] |
[
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pitolisant"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fexofenadine"
],
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
],
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitolisant"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitolisant"
]
]
] |
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Fluconazole may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Fexofenadine and Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Fluconazole may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Fluconazole may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Pitolisant
Fluconazole may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Pitolisant
|
DB08882
|
DB13007
| 1,281
| 1,060
|
[
"DDInter1070",
"DDInter642"
] |
Linagliptin
|
Enfortumab vedotin
|
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
|
Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4. The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics and it was first approved for use in the United States in December 2019 under the brand name Padcev<sup>TM</sup>. Enfortumab vedotin was later approved by the European Commission on April 13, 2022.
|
Moderate
| 1
|
[
[
[
1281,
24,
1060
]
],
[
[
1281,
24,
1604
],
[
1604,
23,
1060
]
],
[
[
1281,
63,
590
],
[
590,
24,
1060
]
],
[
[
1281,
24,
1296
],
[
1296,
24,
1060
]
],
[
[
1281,
40,
1002
],
[
1002,
24,
1060
]
],
[
[
1281,
63,
609
],
[
609,
25,
1060
]
],
[
[
1281,
24,
1604
],
[
1604,
63,
590
],
[
590,
24,
1060
]
],
[
[
1281,
24,
129
],
[
129,
64,
1593
],
[
1593,
24,
1060
]
],
[
[
1281,
63,
590
],
[
590,
24,
1604
],
[
1604,
23,
1060
]
],
[
[
1281,
63,
1179
],
[
1179,
24,
590
],
[
590,
24,
1060
]
]
] |
[
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Linagliptin",
"{u} (Compound) resembles {v} (Compound)",
"Alogliptin"
],
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
]
] |
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Linagliptin (Compound) resembles Alogliptin (Compound) and Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Enfortumab vedotin
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
|
DB08820
|
DB08932
| 1,478
| 1,398
|
[
"DDInter997",
"DDInter1111"
] |
Ivacaftor
|
Macitentan
|
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result
|
Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity.
|
Moderate
| 1
|
[
[
[
1478,
24,
1398
]
],
[
[
1478,
6,
1829
],
[
1829,
45,
1398
]
],
[
[
1478,
21,
29429
],
[
29429,
60,
1398
]
],
[
[
1478,
25,
283
],
[
283,
63,
1398
]
],
[
[
1478,
63,
1101
],
[
1101,
24,
1398
]
],
[
[
1478,
24,
1619
],
[
1619,
63,
1398
]
],
[
[
1478,
64,
1419
],
[
1419,
24,
1398
]
],
[
[
1478,
24,
850
],
[
850,
24,
1398
]
],
[
[
1478,
25,
1593
],
[
1593,
24,
1398
]
],
[
[
1478,
64,
609
],
[
609,
25,
1398
]
]
] |
[
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macitentan"
]
],
[
[
"Ivacaftor",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
"Macitentan"
]
],
[
[
"Ivacaftor",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation NOS"
],
[
"Infestation NOS",
"{u} (Side Effect) is caused by {v} (Compound)",
"Macitentan"
]
],
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macitentan"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macitentan"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macitentan"
]
],
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macitentan"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macitentan"
]
],
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macitentan"
]
],
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macitentan"
]
]
] |
Ivacaftor (Compound) binds ALB (Gene) and ALB (Gene) is bound by Macitentan (Compound)
Ivacaftor (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Macitentan (Compound)
Ivacaftor may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Macitentan
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Macitentan
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Macitentan
Ivacaftor may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Macitentan
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Macitentan
Ivacaftor may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Macitentan
Ivacaftor may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Macitentan
|
DB01138
|
DB08901
| 804
| 1,468
|
[
"DDInter1726",
"DDInter1492"
] |
Sulfinpyrazone
|
Ponatinib
|
A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
|
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
|
Major
| 2
|
[
[
[
804,
25,
1468
]
],
[
[
804,
24,
478
],
[
478,
24,
1468
]
],
[
[
804,
6,
3486
],
[
3486,
45,
1468
]
],
[
[
804,
7,
9242
],
[
9242,
46,
1468
]
],
[
[
804,
18,
4930
],
[
4930,
57,
1468
]
],
[
[
804,
24,
1135
],
[
1135,
62,
1468
]
],
[
[
804,
24,
384
],
[
384,
63,
1468
]
],
[
[
804,
63,
1195
],
[
1195,
24,
1468
]
],
[
[
804,
25,
4
],
[
4,
24,
1468
]
],
[
[
804,
62,
168
],
[
168,
24,
1468
]
]
] |
[
[
[
"Sulfinpyrazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} (Compound) upregulates {v} (Gene)",
"WDR7"
],
[
"WDR7",
"{u} (Gene) is upregulated by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} (Compound) downregulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
]
] |
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Sulfinpyrazone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ponatinib (Compound)
Sulfinpyrazone (Compound) upregulates WDR7 (Gene) and WDR7 (Gene) is upregulated by Ponatinib (Compound)
Sulfinpyrazone (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Ponatinib (Compound)
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Sulfinpyrazone may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Sulfinpyrazone may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
|
DB11978
|
DB13139
| 124
| 1,032
|
[
"DDInter822",
"DDInter1063"
] |
Glasdegib
|
Levosalbutamol
|
Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one
|
Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol).
|
Moderate
| 1
|
[
[
[
124,
24,
1032
]
],
[
[
124,
64,
1220
],
[
1220,
23,
1032
]
],
[
[
124,
64,
1618
],
[
1618,
24,
1032
]
],
[
[
124,
63,
594
],
[
594,
24,
1032
]
],
[
[
124,
25,
982
],
[
982,
63,
1032
]
],
[
[
124,
24,
484
],
[
484,
24,
1032
]
],
[
[
124,
64,
351
],
[
351,
25,
1032
]
],
[
[
124,
25,
877
],
[
877,
25,
1032
]
],
[
[
124,
64,
1220
],
[
1220,
40,
218
],
[
218,
23,
1032
]
],
[
[
124,
64,
1618
],
[
1618,
63,
1220
],
[
1220,
23,
1032
]
]
] |
[
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Beclomethasone dipropionate"
],
[
"Beclomethasone dipropionate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levosalbutamol"
]
]
] |
Glasdegib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Glasdegib may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Glasdegib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Glasdegib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Levosalbutamol
Glasdegib may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Levosalbutamol
Glasdegib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone (Compound) resembles Beclomethasone dipropionate (Compound) and Beclomethasone dipropionate may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Glasdegib may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
|
DB11988
|
DB13007
| 270
| 1,060
|
[
"DDInter1321",
"DDInter642"
] |
Ocrelizumab
|
Enfortumab vedotin
|
Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS.[A18875,A251745] MS is a chronic, inflammatory, autoimmune disease of the central nervous system that leads to neurological disabilities and a significantly reduced quality of life. Most patients with MS experience episodes of relapses with worsening function, followed by recovery periods or remissions. Primary progressive multiple sclerosis (PPMS) accounts for 10-15% of the overall population of patients with MS, and leads to the gradual worsening of neurologic disability
|
Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4. The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics and it was first approved for use in the United States in December 2019 under the brand name Padcev<sup>TM</sup>. Enfortumab vedotin was later approved by the European Commission on April 13, 2022.
|
Moderate
| 1
|
[
[
[
270,
24,
1060
]
],
[
[
270,
63,
350
],
[
350,
24,
1060
]
],
[
[
270,
64,
1011
],
[
1011,
25,
1060
]
],
[
[
270,
63,
507
],
[
507,
25,
1060
]
],
[
[
270,
25,
676
],
[
676,
64,
1060
]
],
[
[
270,
63,
350
],
[
350,
63,
1593
],
[
1593,
24,
1060
]
],
[
[
270,
63,
58
],
[
58,
24,
350
],
[
350,
24,
1060
]
],
[
[
270,
63,
147
],
[
147,
24,
129
],
[
129,
23,
1060
]
],
[
[
270,
63,
1362
],
[
1362,
25,
1604
],
[
1604,
23,
1060
]
],
[
[
270,
63,
1480
],
[
1480,
64,
1604
],
[
1604,
23,
1060
]
]
] |
[
[
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Ocrelizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
],
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Ocrelizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enfortumab vedotin"
]
]
] |
Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Ocrelizumab may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Enfortumab vedotin
Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam and Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Enfortumab vedotin
Ocrelizumab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Enfortumab vedotin
Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
|
DB00262
|
DB00305
| 552
| 377
|
[
"DDInter302",
"DDInter1232"
] |
Carmustine
|
Mitomycin
|
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
|
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies. Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC) - as well as adjunctly to _ab externo_ glaucoma surgeries.
|
Moderate
| 1
|
[
[
[
552,
24,
377
]
],
[
[
552,
54,
19138
],
[
19138,
15,
377
]
],
[
[
552,
21,
28680
],
[
28680,
60,
377
]
],
[
[
552,
23,
246
],
[
246,
62,
377
]
],
[
[
552,
62,
1176
],
[
1176,
23,
377
]
],
[
[
552,
24,
450
],
[
450,
63,
377
]
],
[
[
552,
63,
440
],
[
440,
24,
377
]
],
[
[
552,
35,
37
],
[
37,
63,
377
]
],
[
[
552,
24,
329
],
[
329,
24,
377
]
],
[
[
552,
25,
1624
],
[
1624,
64,
377
]
]
] |
[
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mitomycin"
]
],
[
[
"Carmustine",
"{u} (Compound) is included by {v} (Pharmacologic Class)",
"Alkylating Activity"
],
[
"Alkylating Activity",
"{u} (Pharmacologic Class) includes {v} (Compound)",
"Mitomycin"
]
],
[
[
"Carmustine",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mitomycin"
]
],
[
[
"Carmustine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mitomycin"
]
],
[
[
"Carmustine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mitomycin"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mitomycin"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
],
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mitomycin"
]
],
[
[
"Carmustine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mitomycin"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bleomycin"
],
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mitomycin"
]
],
[
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
],
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mitomycin"
]
]
] |
Carmustine (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Mitomycin (Compound)
Carmustine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Mitomycin (Compound)
Carmustine may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Mitomycin
Carmustine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Mitomycin
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin
Carmustine (Compound) resembles Lomustine (Compound) and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Bleomycin and Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin
Carmustine may lead to a major life threatening interaction when taken with Rotavirus vaccine and Rotavirus vaccine may lead to a major life threatening interaction when taken with Mitomycin
|
DB08865
|
DB11967
| 1,593
| 710
|
[
"DDInter448",
"DDInter210"
] |
Crizotinib
|
Binimetinib
|
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used
|
Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.
|
Moderate
| 1
|
[
[
[
1593,
24,
710
]
],
[
[
1593,
64,
441
],
[
441,
24,
710
]
],
[
[
1593,
25,
1293
],
[
1293,
24,
710
]
],
[
[
1593,
25,
68
],
[
68,
63,
710
]
],
[
[
1593,
24,
951
],
[
951,
24,
710
]
],
[
[
1593,
63,
336
],
[
336,
24,
710
]
],
[
[
1593,
24,
733
],
[
733,
63,
710
]
],
[
[
1593,
23,
466
],
[
466,
63,
710
]
],
[
[
1593,
23,
271
],
[
271,
24,
710
]
],
[
[
1593,
62,
307
],
[
307,
24,
710
]
]
] |
[
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valbenazine"
],
[
"Valbenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
],
[
"Troleandomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
],
[
"Eslicarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Crizotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Crizotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Crizotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
]
] |
Crizotinib may lead to a major life threatening interaction when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Crizotinib may lead to a major life threatening interaction when taken with Valbenazine and Valbenazine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Crizotinib may lead to a major life threatening interaction when taken with Troleandomycin and Troleandomycin may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine and Eslicarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
|
DB00845
|
DB09330
| 1,490
| 985
|
[
"DDInter406",
"DDInter1352"
] |
Clofazimine
|
Osimertinib
|
Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis treatments such as [rifampicin] and [isoniazid].
|
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931]
|
Major
| 2
|
[
[
[
1490,
25,
985
]
],
[
[
1490,
23,
112
],
[
112,
23,
985
]
],
[
[
1490,
24,
480
],
[
480,
24,
985
]
],
[
[
1490,
24,
657
],
[
657,
63,
985
]
],
[
[
1490,
63,
1181
],
[
1181,
24,
985
]
],
[
[
1490,
64,
11
],
[
11,
25,
985
]
],
[
[
1490,
24,
594
],
[
594,
25,
985
]
],
[
[
1490,
25,
1069
],
[
1069,
25,
985
]
],
[
[
1490,
24,
484
],
[
484,
64,
985
]
],
[
[
1490,
63,
1674
],
[
1674,
25,
985
]
]
] |
[
[
[
"Clofazimine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Clofazimine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
],
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Clofazimine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Clofazimine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
]
] |
Clofazimine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Clofazimine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Osimertinib
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Osimertinib
Clofazimine may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Osimertinib
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may lead to a major life threatening interaction when taken with Osimertinib
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may lead to a major life threatening interaction when taken with Osimertinib
|
DB00586
|
DB14761
| 1,512
| 242
|
[
"DDInter537",
"DDInter1578"
] |
Diclofenac
|
Remdesivir
|
Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the
|
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues. Remdesivir (GS-5734) is an adenosine triphosphate analogue first described in the literature in 2016 as a potential treatment for Ebola.[A191379, A222393] Broad antiviral activity of remdesivir is suggested by its mechanism of action, and to date, it has demonstrated _in vitro_ activity against the _Arenaviridae_, _Flaviviridae_, _Filoviridae_, _Paramyxoviridae_, _Pneumoviridae_, and _Coronaviridae_ viral families. Remdesivir activity against the _Coronaviridae_ family was first demonstrated in 2017, leading to considerable interest in remdesivir as a possible treatment for COVID-19.[A191427, A198810] Remdesivir was confirmed as a non-obligate chain terminator of RdRp from SARS-CoV-2 and the related SARS-CoV and MERS-CoV, and has been investigated in multiple COVID-19 clinical trials.[L12174, L12177] After initially being granted an FDA Emergency Use Authorization (EUA) on May 1st, 2020, remdesivir was fully approved by the FDA for the treatment of COVID-19 on October 22, 2020. Remdesivir is currently marketed under the trademark name VEKLURY by Gilead Sciences Inc. Remdesivir was also approved by the European Commission on July 3, 2020. Remdesivir in combination with [baricitinib] for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on November 19, 2020.
|
Moderate
| 1
|
[
[
[
1512,
24,
242
]
],
[
[
1512,
25,
1377
],
[
1377,
24,
242
]
],
[
[
1512,
24,
129
],
[
129,
24,
242
]
],
[
[
1512,
63,
482
],
[
482,
24,
242
]
],
[
[
1512,
64,
663
],
[
663,
24,
242
]
],
[
[
1512,
25,
1377
],
[
1377,
25,
1130
],
[
1130,
24,
242
]
],
[
[
1512,
24,
129
],
[
129,
63,
467
],
[
467,
24,
242
]
],
[
[
1512,
63,
482
],
[
482,
24,
1130
],
[
1130,
24,
242
]
],
[
[
1512,
24,
848
],
[
848,
25,
1377
],
[
1377,
24,
242
]
],
[
[
1512,
25,
1468
],
[
1468,
63,
467
],
[
467,
24,
242
]
]
] |
[
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pioglitazone"
],
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
]
] |
Diclofenac may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Diclofenac may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Diclofenac may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Diclofenac may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
|
DB06402
|
DB11978
| 1,079
| 124
|
[
"DDInter1756",
"DDInter822"
] |
Telavancin
|
Glasdegib
|
Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.
|
Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.[A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined with low dose cytarabine. Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due to glasdegib's more favorable side effects profile.
|
Moderate
| 1
|
[
[
[
1079,
24,
124
]
],
[
[
1079,
62,
112
],
[
112,
23,
124
]
],
[
[
1079,
63,
79
],
[
79,
24,
124
]
],
[
[
1079,
64,
629
],
[
629,
24,
124
]
],
[
[
1079,
24,
1250
],
[
1250,
24,
124
]
],
[
[
1079,
24,
823
],
[
823,
63,
124
]
],
[
[
1079,
1,
968
],
[
968,
24,
124
]
],
[
[
1079,
64,
702
],
[
702,
25,
124
]
],
[
[
1079,
25,
982
],
[
982,
64,
124
]
],
[
[
1079,
25,
1154
],
[
1154,
25,
124
]
]
] |
[
[
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Telavancin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glasdegib"
]
],
[
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Telavancin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Telavancin",
"{u} (Compound) resembles {v} (Compound)",
"Oritavancin"
],
[
"Oritavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Telavancin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
],
[
[
"Telavancin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
],
[
[
"Telavancin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
]
] |
Telavancin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Telavancin may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Telavancin (Compound) resembles Oritavancin (Compound) and Oritavancin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Telavancin may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Glasdegib
Telavancin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Glasdegib
Telavancin may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Glasdegib
|
DB00218
|
DB01268
| 1,176
| 1,151
|
[
"DDInter1247",
"DDInter1731"
] |
Moxifloxacin
|
Sunitinib
|
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
|
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
|
Major
| 2
|
[
[
[
1176,
25,
1151
]
],
[
[
1176,
21,
29662
],
[
29662,
60,
1151
]
],
[
[
1176,
23,
112
],
[
112,
23,
1151
]
],
[
[
1176,
25,
1148
],
[
1148,
24,
1151
]
],
[
[
1176,
25,
1250
],
[
1250,
63,
1151
]
],
[
[
1176,
24,
720
],
[
720,
63,
1151
]
],
[
[
1176,
24,
482
],
[
482,
24,
1151
]
],
[
[
1176,
64,
1179
],
[
1179,
24,
1151
]
],
[
[
1176,
63,
1324
],
[
1324,
24,
1151
]
],
[
[
1176,
1,
739
],
[
739,
24,
1151
]
]
] |
[
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Candida infection"
],
[
"Candida infection",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sunitinib"
]
],
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
],
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
]
] |
Moxifloxacin (Compound) causes Candida infection (Side Effect) and Candida infection (Side Effect) is caused by Sunitinib (Compound)
Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib
Moxifloxacin may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Moxifloxacin may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Moxifloxacin may lead to a major life threatening interaction when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Moxifloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
|
DB00422
|
DB09080
| 895
| 144
|
[
"DDInter1189",
"DDInter1331"
] |
Methylphenidate
|
Olodaterol
|
Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve the following group of developmentally inappropriate symptoms associated with ADHD: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Long-acting formulations of psychostimulants such as methylphenidate,, and are considered the most effective and widely used treatment for ADHD, and are considered first-line options for children, adolescents, and adults as recommended by CADDRA (Canadian ADHD Resource Alliance). CADDRA recommends the use of methylphenidate due to long term studies, of over twenty years in duration, which show methylphenid
|
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated symptoms such as shortness of breath, cough, and sputum production. Single doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing. A once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period. Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma.
|
Moderate
| 1
|
[
[
[
895,
24,
144
]
],
[
[
895,
24,
1445
],
[
1445,
24,
144
]
],
[
[
895,
1,
1177
],
[
1177,
24,
144
]
],
[
[
895,
63,
1636
],
[
1636,
24,
144
]
],
[
[
895,
24,
659
],
[
659,
63,
144
]
],
[
[
895,
25,
1053
],
[
1053,
24,
144
]
],
[
[
895,
25,
1629
],
[
1629,
63,
144
]
],
[
[
895,
25,
290
],
[
290,
25,
144
]
],
[
[
895,
24,
1445
],
[
1445,
24,
1592
],
[
1592,
24,
144
]
],
[
[
895,
24,
1264
],
[
1264,
62,
1247
],
[
1247,
23,
144
]
]
] |
[
[
[
"Methylphenidate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Methylphenidate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Methylphenidate",
"{u} (Compound) resembles {v} (Compound)",
"Dexmethylphenidate"
],
[
"Dexmethylphenidate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Methylphenidate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Methylphenidate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Methylphenidate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Methylphenidate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Methylphenidate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
],
[
"Cocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olodaterol"
]
],
[
[
"Methylphenidate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
],
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Methylphenidate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Olodaterol"
]
]
] |
Methylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Methylphenidate (Compound) resembles Dexmethylphenidate (Compound) and Dex
Methylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Methylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Methylphenidate may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Methylphenidate may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Methylphenidate may lead to a major life threatening interaction when taken with Cocaine and Cocaine may lead to a major life threatening interaction when taken with Olodaterol
Methylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Nebivolol and Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Methylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
|
DB00425
|
DB08881
| 558
| 868
|
[
"DDInter1970",
"DDInter1925"
] |
Zolpidem
|
Vemurafenib
|
Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of sleep, and decreases the number of awakenings during sleep in patients with temporary (transient) insomnia. It is available in both immediate acting and extended release forms [FDA label],. Its tolerability profile is favorable when administered according to the manufacturer’s instructions, with a low risk of drug withdrawal, drug dependence, and drug tolerance. In addition, zolpidem improves sleep quality in patients suffering from chronic insomnia and can show mild muscle relaxant properties. Research also shows that zolpidem is rapid and effective in restoring brain function for patients in a vegetative state following brain injury. This drug has the propensity to completely or partially
|
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
|
Moderate
| 1
|
[
[
[
558,
24,
868
]
],
[
[
558,
6,
8374
],
[
8374,
45,
868
]
],
[
[
558,
21,
28847
],
[
28847,
60,
868
]
],
[
[
558,
24,
760
],
[
760,
63,
868
]
],
[
[
558,
63,
1324
],
[
1324,
24,
868
]
],
[
[
558,
24,
723
],
[
723,
24,
868
]
],
[
[
558,
24,
478
],
[
478,
25,
868
]
],
[
[
558,
63,
702
],
[
702,
25,
868
]
],
[
[
558,
24,
129
],
[
129,
64,
868
]
],
[
[
558,
6,
8374
],
[
8374,
45,
11285
],
[
11285,
1,
868
]
]
] |
[
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Zolpidem",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Zolpidem",
"{u} (Compound) causes {v} (Side Effect)",
"Eye disorder"
],
[
"Eye disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Zolpidem",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Etoricoxib"
],
[
"Etoricoxib",
"{u} (Compound) resembles {v} (Compound)",
"Vemurafenib"
]
]
] |
Zolpidem (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Zolpidem (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Vemurafenib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Vemurafenib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Vemurafenib
Zolpidem (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
|
DB00798
|
DB01190
| 1,132
| 568
|
[
"DDInter815",
"DDInter398"
] |
Gentamicin
|
Clindamycin
|
Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by _Pseudomonas aeruginosa_.[A233325,A234359,A234364] There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.[A234359,A234364] Although gentamicin is well-established and may be used in a variety of clinical applications,
|
Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis. Clindamycin is derived from, and has largely replaced, [lincomycin], a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from _Streptomyces lincolnensis_ found in a soil sample.
|
Moderate
| 1
|
[
[
[
1132,
24,
568
]
],
[
[
1132,
21,
29157
],
[
29157,
60,
568
]
],
[
[
1132,
25,
276
],
[
276,
63,
568
]
],
[
[
1132,
64,
190
],
[
190,
24,
568
]
],
[
[
1132,
63,
955
],
[
955,
24,
568
]
],
[
[
1132,
24,
884
],
[
884,
63,
568
]
],
[
[
1132,
25,
648
],
[
648,
24,
568
]
],
[
[
1132,
24,
1096
],
[
1096,
24,
568
]
],
[
[
1132,
21,
28680
],
[
28680,
60,
1208
],
[
1208,
1,
568
]
],
[
[
1132,
21,
29015
],
[
29015,
60,
609
],
[
609,
63,
568
]
]
] |
[
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Gentamicin",
"{u} (Compound) causes {v} (Side Effect)",
"Application site pain"
],
[
"Application site pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clindamycin"
]
],
[
[
"Gentamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rapacuronium"
],
[
"Rapacuronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Gentamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Succinylcholine"
],
[
"Succinylcholine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolate mofetil"
],
[
"Mycophenolate mofetil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
],
[
"Indium In-111 oxyquinoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Gentamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxacurium"
],
[
"Doxacurium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Gentamicin",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lincomycin"
],
[
"Lincomycin",
"{u} (Compound) resembles {v} (Compound)",
"Clindamycin"
]
],
[
[
"Gentamicin",
"{u} (Compound) causes {v} (Side Effect)",
"Eosinophilia"
],
[
"Eosinophilia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
]
] |
Gentamicin (Compound) causes Application site pain (Side Effect) and Application site pain (Side Effect) is caused by Clindamycin (Compound)
Gentamicin may lead to a major life threatening interaction when taken with Rapacuronium and Rapacuronium may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin
Gentamicin may lead to a major life threatening interaction when taken with Succinylcholine and Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline and Indium In-111 oxyquinoline may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin
Gentamicin may lead to a major life threatening interaction when taken with Doxacurium and Doxacurium may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin
Gentamicin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Lincomycin (Compound) and Lincomycin (Compound) resembles Clindamycin (Compound)
Gentamicin (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Clarithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin
|
DB01043
|
DB01142
| 108
| 1,264
|
[
"DDInter1146",
"DDInter593"
] |
Memantine
|
Doxepin
|
Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease. Memantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and excessive stimulation in Alzheimer's Disease. In 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million. Almost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050. In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or
|
Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics.
|
Moderate
| 1
|
[
[
[
108,
24,
1264
]
],
[
[
108,
24,
401
],
[
401,
24,
1264
]
],
[
[
108,
63,
832
],
[
832,
24,
1264
]
],
[
[
108,
6,
10215
],
[
10215,
45,
1264
]
],
[
[
108,
21,
29226
],
[
29226,
60,
1264
]
],
[
[
108,
24,
103
],
[
103,
63,
1264
]
],
[
[
108,
62,
752
],
[
752,
24,
1264
]
],
[
[
108,
24,
1376
],
[
1376,
35,
1264
]
],
[
[
108,
24,
820
],
[
820,
74,
1264
]
],
[
[
108,
24,
401
],
[
401,
74,
508
],
[
508,
24,
1264
]
]
] |
[
[
[
"Memantine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Memantine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Memantine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Memantine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Doxepin"
]
],
[
[
"Memantine",
"{u} (Compound) causes {v} (Side Effect)",
"Sinusitis"
],
[
"Sinusitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Doxepin"
]
],
[
[
"Memantine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
],
[
"Acrivastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Memantine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Memantine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Memantine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Memantine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
]
] |
Memantine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Memantine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Memantine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Doxepin (Compound)
Memantine (Compound) causes Sinusitis (Side Effect) and Sinusitis (Side Effect) is caused by Doxepin (Compound)
Memantine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine and Acrivastine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Memantine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Memantine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Doxepin (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Memantine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Doxepin (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Memantine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine (Compound) resembles Promazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
|
DB08865
|
DB12267
| 1,593
| 1,476
|
[
"DDInter448",
"DDInter233"
] |
Crizotinib
|
Brigatinib
|
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used
|
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
|
Major
| 2
|
[
[
[
1593,
25,
1476
]
],
[
[
1593,
25,
1612
],
[
1612,
23,
1476
]
],
[
[
1593,
63,
629
],
[
629,
24,
1476
]
],
[
[
1593,
24,
951
],
[
951,
24,
1476
]
],
[
[
1593,
64,
918
],
[
918,
24,
1476
]
],
[
[
1593,
24,
829
],
[
829,
63,
1476
]
],
[
[
1593,
25,
1456
],
[
1456,
24,
1476
]
],
[
[
1593,
25,
1598
],
[
1598,
63,
1476
]
],
[
[
1593,
62,
479
],
[
479,
24,
1476
]
],
[
[
1593,
23,
466
],
[
466,
63,
1476
]
]
] |
[
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brigatinib"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
],
[
"Ubrogepant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tazemetostat"
],
[
"Tazemetostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Crizotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Crizotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
]
] |
Crizotinib may lead to a major life threatening interaction when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Crizotinib may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant and Ubrogepant may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Crizotinib may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Crizotinib may lead to a major life threatening interaction when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
|
DB00934
|
DB00981
| 413
| 1,528
|
[
"DDInter1124",
"DDInter1463"
] |
Maprotiline
|
Physostigmine (ophthalmic)
|
Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive disorder. Maprotiline is effective at reducing symptoms of anxiety associated with depression.
|
Physostigmine is a carbamate ester and an indole alkaloid. It has a role as a miotic, an EC 3.1.1.8 (cholinesterase) inhibitor and an antidote to curare poisoning.
|
Moderate
| 1
|
[
[
[
413,
24,
1528
]
],
[
[
413,
21,
28751
],
[
28751,
60,
1528
]
],
[
[
413,
24,
1511
],
[
1511,
63,
1528
]
],
[
[
413,
63,
543
],
[
543,
24,
1528
]
],
[
[
413,
1,
1302
],
[
1302,
24,
1528
]
],
[
[
413,
25,
1011
],
[
1011,
63,
1528
]
],
[
[
413,
25,
497
],
[
497,
64,
1528
]
],
[
[
413,
21,
28751
],
[
28751,
60,
87
],
[
87,
24,
1528
]
],
[
[
413,
21,
28658
],
[
28658,
60,
1592
],
[
1592,
63,
1528
]
],
[
[
413,
24,
1511
],
[
1511,
21,
28658
],
[
28658,
60,
1528
]
]
] |
[
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Maprotiline",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Physostigmine"
]
],
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Maprotiline",
"{u} (Compound) resembles {v} (Compound)",
"Protriptyline"
],
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Maprotiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Maprotiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Physostigmine"
]
],
[
[
"Maprotiline",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amoxapine"
],
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Maprotiline",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nebivolol"
],
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Physostigmine"
]
]
] |
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Maprotiline (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Physostigmine (Compound)
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Maprotiline (Compound) resembles Protriptyline (Compound) and Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Maprotiline may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Maprotiline may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Physostigmine
Maprotiline (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Amoxapine (Compound) and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Maprotiline (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Nebivolol (Compound) and Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Physostigmine (Compound)
|
DB00005
|
DB00552
| 1,057
| 1,238
|
[
"DDInter687",
"DDInter1425"
] |
Etanercept
|
Pentostatin
|
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).
|
A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
|
Major
| 2
|
[
[
[
1057,
25,
1238
]
],
[
[
1057,
25,
1083
],
[
1083,
40,
1238
]
],
[
[
1057,
25,
1426
],
[
1426,
1,
1238
]
],
[
[
1057,
24,
1477
],
[
1477,
40,
1238
]
],
[
[
1057,
25,
1648
],
[
1648,
24,
1238
]
],
[
[
1057,
25,
995
],
[
995,
63,
1238
]
],
[
[
1057,
24,
599
],
[
599,
24,
1238
]
],
[
[
1057,
24,
1270
],
[
1270,
63,
1238
]
],
[
[
1057,
25,
908
],
[
908,
64,
1238
]
],
[
[
1057,
25,
695
],
[
695,
25,
1238
]
]
] |
[
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentostatin"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
],
[
"Trifluridine",
"{u} (Compound) resembles {v} (Compound)",
"Pentostatin"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Azacitidine"
],
[
"Azacitidine",
"{u} (Compound) resembles {v} (Compound)",
"Pentostatin"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
],
[
"Telbivudine",
"{u} (Compound) resembles {v} (Compound)",
"Pentostatin"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxyurea"
],
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
],
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentostatin"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentostatin"
]
]
] |
Etanercept may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine (Compound) resembles Pentostatin (Compound)
Etanercept may lead to a major life threatening interaction when taken with Azacitidine and Azacitidine (Compound) resembles Pentostatin (Compound)
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine and Telbivudine (Compound) resembles Pentostatin (Compound)
Etanercept may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin
Etanercept may lead to a major life threatening interaction when taken with Hydroxyurea and Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin
Etanercept may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Pentostatin
Etanercept may lead to a major life threatening interaction when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Pentostatin
|
DB00092
|
DB06595
| 58
| 1,491
|
[
"DDInter40",
"DDInter1214"
] |
Alefacept
|
Midostaurin
|
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
|
Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
|
Moderate
| 1
|
[
[
[
58,
24,
1491
]
],
[
[
58,
24,
270
],
[
270,
63,
1491
]
],
[
[
58,
24,
1342
],
[
1342,
24,
1491
]
],
[
[
58,
63,
1184
],
[
1184,
24,
1491
]
],
[
[
58,
25,
1377
],
[
1377,
25,
1491
]
],
[
[
58,
24,
362
],
[
362,
25,
1491
]
],
[
[
58,
24,
1456
],
[
1456,
64,
1491
]
],
[
[
58,
25,
1137
],
[
1137,
64,
1491
]
],
[
[
58,
63,
1057
],
[
1057,
25,
1491
]
],
[
[
58,
24,
270
],
[
270,
63,
1342
],
[
1342,
24,
1491
]
]
] |
[
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
],
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
],
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
],
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
]
] |
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Alefacept may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Midostaurin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may lead to a major life threatening interaction when taken with Midostaurin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may lead to a major life threatening interaction when taken with Midostaurin
Alefacept may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated and Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Midostaurin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Midostaurin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
|
DB00619
|
DB06772
| 1,419
| 310
|
[
"DDInter909",
"DDInter259"
] |
Imatinib
|
Cabazitaxel
|
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
|
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.
|
Moderate
| 1
|
[
[
[
1419,
24,
310
]
],
[
[
1419,
24,
973
],
[
973,
24,
310
]
],
[
[
1419,
6,
7524
],
[
7524,
45,
310
]
],
[
[
1419,
21,
28894
],
[
28894,
60,
310
]
],
[
[
1419,
23,
307
],
[
307,
23,
310
]
],
[
[
1419,
24,
800
],
[
800,
63,
310
]
],
[
[
1419,
63,
798
],
[
798,
24,
310
]
],
[
[
1419,
25,
1598
],
[
1598,
63,
310
]
],
[
[
1419,
25,
171
],
[
171,
24,
310
]
],
[
[
1419,
35,
1468
],
[
1468,
63,
310
]
]
] |
[
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Cabazitaxel"
]
],
[
[
"Imatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac failure"
],
[
"Cardiac failure",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cabazitaxel"
]
],
[
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
],
[
"Duvelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tazemetostat"
],
[
"Tazemetostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
],
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Imatinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
]
] |
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Imatinib (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Cabazitaxel (Compound)
Imatinib (Compound) causes Cardiac failure (Side Effect) and Cardiac failure (Side Effect) is caused by Cabazitaxel (Compound)
Imatinib may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Cabazitaxel
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib and Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Imatinib may lead to a major life threatening interaction when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Imatinib may lead to a major life threatening interaction when taken with Lonafarnib and Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Imatinib (Compound) resembles Ponatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
|
DB00570
|
DB10989
| 147
| 496
|
[
"DDInter1936",
"DDInter858"
] |
Vinblastine
|
Hepatitis A Vaccine
|
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
|
Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infection and safely confers strong protection against the disease caused by infection with this virus.[A199185,L12756] In the US, the approved vaccine is inactivated while live Hepatitis A vaccines are currently available in other countries.
|
Moderate
| 1
|
[
[
[
147,
24,
496
]
],
[
[
147,
24,
1093
],
[
1093,
63,
496
]
],
[
[
147,
24,
4
],
[
4,
24,
496
]
],
[
[
147,
63,
1101
],
[
1101,
24,
496
]
],
[
[
147,
25,
976
],
[
976,
24,
496
]
],
[
[
147,
62,
970
],
[
970,
24,
496
]
],
[
[
147,
23,
896
],
[
896,
24,
496
]
],
[
[
147,
64,
1066
],
[
1066,
24,
496
]
],
[
[
147,
25,
676
],
[
676,
63,
496
]
],
[
[
147,
24,
1093
],
[
1093,
63,
4
],
[
4,
24,
496
]
]
] |
[
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluorouracil"
],
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etoposide"
],
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
]
] |
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Vinblastine may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Fluorouracil and Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Vinblastine may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Vinblastine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
|
DB00046
|
DB00865
| 1,179
| 939
|
[
"DDInter940",
"DDInter187"
] |
Insulin lispro
|
Benzphetamine
|
Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to
|
A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)
|
Moderate
| 1
|
[
[
[
1179,
24,
939
]
],
[
[
1179,
24,
1529
],
[
1529,
1,
939
]
],
[
[
1179,
24,
1161
],
[
1161,
40,
939
]
],
[
[
1179,
24,
401
],
[
401,
63,
939
]
],
[
[
1179,
24,
1674
],
[
1674,
24,
939
]
],
[
[
1179,
24,
73
],
[
73,
25,
939
]
],
[
[
1179,
24,
1039
],
[
1039,
64,
939
]
],
[
[
1179,
24,
1529
],
[
1529,
1,
80
],
[
80,
40,
939
]
],
[
[
1179,
24,
1161
],
[
1161,
40,
1529
],
[
1529,
1,
939
]
],
[
[
1179,
24,
401
],
[
401,
24,
1529
],
[
1529,
1,
939
]
]
] |
[
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
[
"Metamfetamine",
"{u} (Compound) resembles {v} (Compound)",
"Benzphetamine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
],
[
"Selegiline",
"{u} (Compound) resembles {v} (Compound)",
"Benzphetamine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Benzphetamine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Benzphetamine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
[
"Metamfetamine",
"{u} (Compound) resembles {v} (Compound)",
"Amphetamine"
],
[
"Amphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Benzphetamine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
],
[
"Selegiline",
"{u} (Compound) resembles {v} (Compound)",
"Metamfetamine"
],
[
"Metamfetamine",
"{u} (Compound) resembles {v} (Compound)",
"Benzphetamine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
[
"Metamfetamine",
"{u} (Compound) resembles {v} (Compound)",
"Benzphetamine"
]
]
] |
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles Benzphetamine (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Selegiline and Selegiline (Compound) resembles Benzphetamine (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Benzphetamine
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Benzphetamine
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles Amphetamine (Compound) and Amphetamine (Compound) resembles Benzphetamine (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Selegiline and Selegiline (Compound) resembles Metamfetamine (Compound) and Metamfetamine (Compound) resembles Benzphetamine (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles Benzphetamine (Compound)
|
DB01208
|
DB11126
| 945
| 900
|
[
"DDInter1705",
"DDInter276"
] |
Sparfloxacin
|
Calcium gluconate
|
Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.
|
Calcium gluconate is used as mineral supplement and medication when there is insufficient calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets, consequences of hypocalcemia. It can also be taken by mouth but is not recommended by injection into a muscle. Calcium Gluconate Injection, USP is a sterile, nonpyrogenic supersaturated solution of calcium gluconate for intravenous use only. Each mL contains: Calcium gluconate 94 mg; calcium saccharate (tetrahydrate) 4.5 mg; water for injection q.s. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment (6.0 to 8.2). Calcium saccharate provides 6% of the total calcium and stabilizes the supersaturated solution of calcium gluconate. Each 10 mL of the injection provides 93 mg elemental calcium (Ca++) equivalent to 1 g of calcium gluconate.
|
Moderate
| 1
|
[
[
[
945,
24,
900
]
],
[
[
945,
40,
1176
],
[
1176,
24,
900
]
],
[
[
945,
40,
1176
],
[
1176,
1,
739
],
[
739,
24,
900
]
],
[
[
945,
40,
739
],
[
739,
40,
1176
],
[
1176,
24,
900
]
],
[
[
945,
21,
28698
],
[
28698,
60,
729
],
[
729,
24,
900
]
],
[
[
945,
24,
1283
],
[
1283,
62,
729
],
[
729,
24,
900
]
],
[
[
945,
24,
1283
],
[
1283,
24,
933
],
[
933,
63,
900
]
],
[
[
945,
64,
126
],
[
126,
23,
729
],
[
729,
24,
900
]
],
[
[
945,
64,
126
],
[
126,
24,
933
],
[
933,
63,
900
]
],
[
[
945,
24,
1283
],
[
1283,
24,
29
],
[
29,
24,
900
]
]
] |
[
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Sparfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Sparfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Sparfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Sparfloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Penbutolol"
],
[
"Penbutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Penbutolol"
],
[
"Penbutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omadacycline"
],
[
"Omadacycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Penbutolol"
],
[
"Penbutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omadacycline"
],
[
"Omadacycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triethylenetetramine"
],
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
]
] |
Sparfloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Sparfloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Sparfloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Sparfloxacin (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Penbutolol (Compound) and Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Penbutolol and Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline and Omadacycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Sparfloxacin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Penbutolol and Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Sparfloxacin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline and Omadacycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Triethylenetetramine and Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
|
DB00497
|
DB00757
| 828
| 1,166
|
[
"DDInter1366",
"DDInter581"
] |
Oxycodone
|
Dolasetron
|
Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.
|
Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
|
Moderate
| 1
|
[
[
[
828,
24,
1166
]
],
[
[
828,
63,
19
],
[
19,
40,
1166
]
],
[
[
828,
24,
85
],
[
85,
1,
1166
]
],
[
[
828,
6,
12523
],
[
12523,
45,
1166
]
],
[
[
828,
21,
28803
],
[
28803,
60,
1166
]
],
[
[
828,
25,
752
],
[
752,
23,
1166
]
],
[
[
828,
24,
214
],
[
214,
63,
1166
]
],
[
[
828,
1,
560
],
[
560,
63,
1166
]
],
[
[
828,
40,
1516
],
[
1516,
24,
1166
]
],
[
[
828,
40,
314
],
[
314,
63,
1166
]
]
] |
[
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dolasetron"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscyamine",
"{u} (Compound) resembles {v} (Compound)",
"Dolasetron"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} (Compound) resembles {v} (Compound)",
"Dolasetron"
]
],
[
[
"Oxycodone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Dolasetron"
]
],
[
[
"Oxycodone",
"{u} (Compound) causes {v} (Side Effect)",
"Anaemia"
],
[
"Anaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dolasetron"
]
],
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dolasetron"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dolasetron"
]
],
[
[
"Oxycodone",
"{u} (Compound) resembles {v} (Compound)",
"Oxymorphone"
],
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dolasetron"
]
],
[
[
"Oxycodone",
"{u} (Compound) resembles {v} (Compound)",
"Galantamine"
],
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dolasetron"
]
],
[
[
"Oxycodone",
"{u} (Compound) resembles {v} (Compound)",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dolasetron"
]
]
] |
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine (Compound) resembles Dolasetron (Compound)
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine (Compound) resembles Dolasetron (Compound)
Oxycodone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dolasetron (Compound)
Oxycodone (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Dolasetron (Compound)
Oxycodone may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Dolasetron
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron
Oxycodone (Compound) resembles Oxymorphone (Compound) and Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron
Oxycodone (Compound) resembles Galantamine (Compound) and Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron
Oxycodone (Compound) resembles Nalbuphine (Compound) and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron
|
DB00361
|
DB01229
| 134
| 973
|
[
"DDInter1939",
"DDInter1377"
] |
Vinorelbine
|
Paclitaxel
|
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting. A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug.
|
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
|
Moderate
| 1
|
[
[
[
134,
24,
973
]
],
[
[
134,
24,
310
],
[
310,
63,
973
]
],
[
[
134,
5,
11579
],
[
11579,
44,
973
]
],
[
[
134,
6,
8374
],
[
8374,
45,
973
]
],
[
[
134,
7,
9489
],
[
9489,
46,
973
]
],
[
[
134,
18,
5587
],
[
5587,
57,
973
]
],
[
[
134,
7,
4357
],
[
4357,
57,
973
]
],
[
[
134,
21,
28643
],
[
28643,
60,
973
]
],
[
[
134,
23,
945
],
[
945,
23,
973
]
],
[
[
134,
62,
1176
],
[
1176,
23,
973
]
]
] |
[
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Vinorelbine",
"{u} (Compound) treats {v} (Disease)",
"breast cancer"
],
[
"breast cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Vinorelbine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Vinorelbine",
"{u} (Compound) upregulates {v} (Gene)",
"WIF1"
],
[
"WIF1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Vinorelbine",
"{u} (Compound) downregulates {v} (Gene)",
"SCAND1"
],
[
"SCAND1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Vinorelbine",
"{u} (Compound) upregulates {v} (Gene)",
"FHL2"
],
[
"FHL2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Vinorelbine",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Effect) is caused by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Vinorelbine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
]
],
[
[
"Vinorelbine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
]
]
] |
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Vinorelbine (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Paclitaxel (Compound)
Vinorelbine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Paclitaxel (Compound)
Vinorelbine (Compound) upregulates WIF1 (Gene) and WIF1 (Gene) is upregulated by Paclitaxel (Compound)
Vinorelbine (Compound) downregulates SCAND1 (Gene) and SCAND1 (Gene) is downregulated by Paclitaxel (Compound)
Vinorelbine (Compound) upregulates FHL2 (Gene) and FHL2 (Gene) is downregulated by Paclitaxel (Compound)
Vinorelbine (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Paclitaxel (Compound)
Vinorelbine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Paclitaxel
Vinorelbine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Paclitaxel
|
DB00741
|
DB06636
| 167
| 1,623
|
[
"DDInter885",
"DDInter980"
] |
Hydrocortisone
|
Isavuconazonium
|
Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952.
|
Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and parenteral formulations. Due to low solubility in water of isavuconazole on its own, the isovuconazonium formulation is favorable as it has high solubility in water and allows for intravenous administration. This formulation also avoids the use of a cyclodextrin vehicle for solubilization required for intravenous administration of other antifungals such as voriconazole and posaconazole, eliminating concerns of nephrotoxicity associated with cyclodextrin. Isovuconazonium has excellent oral bioavailability, predictable pharmacokinetics, and a good safety profile, making it a reasonable alternative to its few other competitors on the market.[A6913,A6914,A262706] On December 08, 2023, the FDA approved the expanded use of isovuconazonium in pediatric patients for the same indications.
|
Moderate
| 1
|
[
[
[
167,
24,
1623
]
],
[
[
167,
63,
1419
],
[
1419,
24,
1623
]
],
[
[
167,
24,
1213
],
[
1213,
24,
1623
]
],
[
[
167,
24,
214
],
[
214,
63,
1623
]
],
[
[
167,
1,
891
],
[
891,
24,
1623
]
],
[
[
167,
40,
870
],
[
870,
24,
1623
]
],
[
[
167,
25,
976
],
[
976,
63,
1623
]
],
[
[
167,
25,
593
],
[
593,
24,
1623
]
],
[
[
167,
24,
913
],
[
913,
64,
1623
]
],
[
[
167,
24,
609
],
[
609,
25,
1623
]
]
] |
[
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isavuconazonium"
]
]
] |
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Hydrocortisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Hydrocortisone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Hydrocortisone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Isavuconazonium
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Isavuconazonium
|
DB09343
|
DB12267
| 750
| 1,476
|
[
"DDInter1816",
"DDInter233"
] |
Tipiracil
|
Brigatinib
|
Tipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism. TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, or with an anti-VEGF or anti-EGFR therapy.
|
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
|
Moderate
| 1
|
[
[
[
750,
24,
1476
]
],
[
[
750,
24,
1619
],
[
1619,
63,
1476
]
],
[
[
750,
24,
927
],
[
927,
24,
1476
]
],
[
[
750,
63,
752
],
[
752,
24,
1476
]
],
[
[
750,
63,
303
],
[
303,
25,
1476
]
],
[
[
750,
24,
351
],
[
351,
25,
1476
]
],
[
[
750,
24,
1619
],
[
1619,
63,
1612
],
[
1612,
23,
1476
]
],
[
[
750,
24,
927
],
[
927,
24,
1612
],
[
1612,
23,
1476
]
],
[
[
750,
63,
752
],
[
752,
23,
1135
],
[
1135,
23,
1476
]
],
[
[
750,
63,
303
],
[
303,
24,
629
],
[
629,
24,
1476
]
]
] |
[
[
[
"Tipiracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Tipiracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Tipiracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Tipiracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Tipiracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Tipiracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Tipiracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brigatinib"
]
],
[
[
"Tipiracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brigatinib"
]
],
[
[
"Tipiracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brigatinib"
]
],
[
[
"Tipiracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
]
] |
Tipiracil may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Tipiracil may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Tipiracil may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Tipiracil may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may lead to a major life threatening interaction when taken with Brigatinib
Tipiracil may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Brigatinib
Tipiracil may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Tipiracil may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Tipiracil may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Tipiracil may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
|
DB00280
|
DB01268
| 494
| 1,151
|
[
"DDInter575",
"DDInter1731"
] |
Disopyramide
|
Sunitinib
|
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
|
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
|
Major
| 2
|
[
[
[
494,
25,
1151
]
],
[
[
494,
24,
1311
],
[
1311,
1,
1151
]
],
[
[
494,
6,
8374
],
[
8374,
45,
1151
]
],
[
[
494,
7,
16192
],
[
16192,
46,
1151
]
],
[
[
494,
21,
29170
],
[
29170,
60,
1151
]
],
[
[
494,
23,
112
],
[
112,
23,
1151
]
],
[
[
494,
25,
1148
],
[
1148,
24,
1151
]
],
[
[
494,
25,
1250
],
[
1250,
63,
1151
]
],
[
[
494,
24,
1296
],
[
1296,
63,
1151
]
],
[
[
494,
63,
1179
],
[
1179,
24,
1151
]
]
] |
[
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} (Compound) resembles {v} (Compound)",
"Sunitinib"
]
],
[
[
"Disopyramide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Disopyramide",
"{u} (Compound) upregulates {v} (Gene)",
"KIAA0355"
],
[
"KIAA0355",
"{u} (Gene) is upregulated by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Disopyramide",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac failure congestive"
],
[
"Cardiac failure congestive",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Disopyramide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sunitinib"
]
],
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
]
] |
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide (Compound) resembles Sunitinib (Compound)
Disopyramide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sunitinib (Compound)
Disopyramide (Compound) upregulates KIAA0355 (Gene) and KIAA0355 (Gene) is upregulated by Sunitinib (Compound)
Disopyramide (Compound) causes Cardiac failure congestive (Side Effect) and Cardiac failure congestive (Side Effect) is caused by Sunitinib (Compound)
Disopyramide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib
Disopyramide may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Disopyramide may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
|
DB00224
|
DB12267
| 215
| 1,476
|
[
"DDInter917",
"DDInter233"
] |
Indinavir
|
Brigatinib
|
A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem]
|
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
|
Major
| 2
|
[
[
[
215,
25,
1476
]
],
[
[
215,
25,
1135
],
[
1135,
23,
1476
]
],
[
[
215,
63,
168
],
[
168,
23,
1476
]
],
[
[
215,
25,
629
],
[
629,
24,
1476
]
],
[
[
215,
63,
176
],
[
176,
24,
1476
]
],
[
[
215,
24,
379
],
[
379,
24,
1476
]
],
[
[
215,
24,
1385
],
[
1385,
63,
1476
]
],
[
[
215,
25,
982
],
[
982,
63,
1476
]
],
[
[
215,
23,
1374
],
[
1374,
24,
1476
]
],
[
[
215,
40,
1327
],
[
1327,
25,
1476
]
]
] |
[
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brigatinib"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brigatinib"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
],
[
"Semaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Indinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Indinavir",
"{u} (Compound) resembles {v} (Compound)",
"Saquinavir"
],
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
]
] |
Indinavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Indinavir may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Indinavir may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Indinavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Indinavir (Compound) resembles Saquinavir (Compound) and Saquinavir may lead to a major life threatening interaction when taken with Brigatinib
|
DB00188
|
DB01118
| 168
| 33
|
[
"DDInter222",
"DDInter76"
] |
Bortezomib
|
Amiodarone
|
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic
|
Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286]
|
Moderate
| 1
|
[
[
[
168,
24,
33
]
],
[
[
168,
6,
7950
],
[
7950,
45,
33
]
],
[
[
168,
7,
9650
],
[
9650,
46,
33
]
],
[
[
168,
18,
13123
],
[
13123,
46,
33
]
],
[
[
168,
7,
3586
],
[
3586,
57,
33
]
],
[
[
168,
18,
2183
],
[
2183,
57,
33
]
],
[
[
168,
21,
28681
],
[
28681,
60,
33
]
],
[
[
168,
24,
597
],
[
597,
24,
33
]
],
[
[
168,
24,
1683
],
[
1683,
63,
33
]
],
[
[
168,
63,
58
],
[
58,
24,
33
]
]
] |
[
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Bortezomib",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Amiodarone"
]
],
[
[
"Bortezomib",
"{u} (Compound) upregulates {v} (Gene)",
"HMGCS1"
],
[
"HMGCS1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Amiodarone"
]
],
[
[
"Bortezomib",
"{u} (Compound) downregulates {v} (Gene)",
"ELOVL6"
],
[
"ELOVL6",
"{u} (Gene) is upregulated by {v} (Compound)",
"Amiodarone"
]
],
[
[
"Bortezomib",
"{u} (Compound) upregulates {v} (Gene)",
"EZH2"
],
[
"EZH2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Amiodarone"
]
],
[
[
"Bortezomib",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)",
"Amiodarone"
]
],
[
[
"Bortezomib",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amiodarone"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
]
] |
Bortezomib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Amiodarone (Compound)
Bortezomib (Compound) upregulates HMGCS1 (Gene) and HMGCS1 (Gene) is upregulated by Amiodarone (Compound)
Bortezomib (Compound) downregulates ELOVL6 (Gene) and ELOVL6 (Gene) is upregulated by Amiodarone (Compound)
Bortezomib (Compound) upregulates EZH2 (Gene) and EZH2 (Gene) is downregulated by Amiodarone (Compound)
Bortezomib (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Amiodarone (Compound)
Bortezomib (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Amiodarone (Compound)
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone
|
DB01024
|
DB01764
| 1,096
| 805
|
[
"DDInter1252",
"DDInter469"
] |
Mycophenolic acid
|
Dalfopristin
|
Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency. However, mycophenolic acid treatment is more expensive and requires therapeutic drug monitoring to optimize efficacy and minimize toxicity.[A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic
|
Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.
|
Moderate
| 1
|
[
[
[
1096,
24,
805
]
],
[
[
1096,
24,
609
],
[
609,
24,
805
]
],
[
[
1096,
64,
303
],
[
303,
24,
805
]
],
[
[
1096,
25,
676
],
[
676,
63,
805
]
],
[
[
1096,
63,
629
],
[
629,
24,
805
]
],
[
[
1096,
24,
1017
],
[
1017,
63,
805
]
],
[
[
1096,
24,
609
],
[
609,
6,
8374
],
[
8374,
45,
805
]
],
[
[
1096,
64,
303
],
[
303,
6,
8374
],
[
8374,
45,
805
]
],
[
[
1096,
25,
676
],
[
676,
64,
1101
],
[
1101,
23,
805
]
],
[
[
1096,
63,
629
],
[
629,
6,
8374
],
[
8374,
45,
805
]
]
] |
[
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Mycophenolic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Mycophenolic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dalfopristin"
]
],
[
[
"Mycophenolic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dalfopristin"
]
],
[
[
"Mycophenolic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dalfopristin"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dalfopristin"
]
]
] |
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin
Mycophenolic acid may lead to a major life threatening interaction when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin
Mycophenolic acid may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dalfopristin (Compound)
Mycophenolic acid may lead to a major life threatening interaction when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dalfopristin (Compound)
Mycophenolic acid may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Dalfopristin
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dalfopristin (Compound)
|
DB01118
|
DB09079
| 33
| 1,496
|
[
"DDInter76",
"DDInter1296"
] |
Amiodarone
|
Nintedanib
|
Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286]
|
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function. As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.
|
Moderate
| 1
|
[
[
[
33,
24,
1496
]
],
[
[
33,
25,
609
],
[
609,
24,
1496
]
],
[
[
33,
24,
477
],
[
477,
24,
1496
]
],
[
[
33,
63,
267
],
[
267,
24,
1496
]
],
[
[
33,
25,
913
],
[
913,
63,
1496
]
],
[
[
33,
40,
540
],
[
540,
24,
1496
]
],
[
[
33,
64,
702
],
[
702,
24,
1496
]
],
[
[
33,
24,
159
],
[
159,
63,
1496
]
],
[
[
33,
25,
1510
],
[
1510,
25,
1496
]
],
[
[
33,
24,
1017
],
[
1017,
64,
1496
]
]
] |
[
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Amiodarone",
"{u} (Compound) resembles {v} (Compound)",
"Dronedarone"
],
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nintedanib"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nintedanib"
]
]
] |
Amiodarone may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Amiodarone may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Amiodarone (Compound) resembles Dronedarone (Compound) and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Amiodarone may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Amiodarone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Nintedanib
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Nintedanib
|
DB00741
|
DB01018
| 167
| 1,364
|
[
"DDInter885",
"DDInter847"
] |
Hydrocortisone
|
Guanfacine
|
Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952.
|
Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approval on 27 October 1986.
|
Moderate
| 1
|
[
[
[
167,
24,
1364
]
],
[
[
167,
63,
1512
],
[
1512,
1,
1364
]
],
[
[
167,
6,
8374
],
[
8374,
45,
1364
]
],
[
[
167,
21,
28757
],
[
28757,
60,
1364
]
],
[
[
167,
24,
549
],
[
549,
63,
1364
]
],
[
[
167,
1,
891
],
[
891,
24,
1364
]
],
[
[
167,
25,
976
],
[
976,
63,
1364
]
],
[
[
167,
63,
1214
],
[
1214,
24,
1364
]
],
[
[
167,
40,
870
],
[
870,
24,
1364
]
],
[
[
167,
1,
617
],
[
617,
63,
1364
]
]
] |
[
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} (Compound) resembles {v} (Compound)",
"Guanfacine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Guanfacine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Guanfacine"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
],
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
]
]
] |
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) resembles Guanfacine (Compound)
Hydrocortisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Guanfacine (Compound)
Hydrocortisone (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Guanfacine (Compound)
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine
Hydrocortisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine
Hydrocortisone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine
Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine
Hydrocortisone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine
|
DB00405
|
DB00792
| 128
| 832
|
[
"DDInter517",
"DDInter1878"
] |
Dexbrompheniramine
|
Tripelennamine
|
Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.
|
A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically.
|
Moderate
| 1
|
[
[
[
128,
24,
832
]
],
[
[
128,
1,
11775
],
[
11775,
40,
832
]
],
[
[
128,
24,
100
],
[
100,
63,
832
]
],
[
[
128,
24,
649
],
[
649,
1,
832
]
],
[
[
128,
74,
1594
],
[
1594,
24,
832
]
],
[
[
128,
40,
11296
],
[
11296,
1,
832
]
],
[
[
128,
40,
11439
],
[
11439,
40,
832
]
],
[
[
128,
25,
675
],
[
675,
25,
832
]
],
[
[
128,
6,
10104
],
[
10104,
45,
832
]
],
[
[
128,
23,
771
],
[
771,
62,
832
]
]
] |
[
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Dexbrompheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Chloropyramine"
],
[
"Chloropyramine",
"{u} (Compound) resembles {v} (Compound)",
"Tripelennamine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} (Compound) resembles {v} (Compound)",
"Tripelennamine"
]
],
[
[
"Dexbrompheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Dexbrompheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Bromodiphenhydramine"
],
[
"Bromodiphenhydramine",
"{u} (Compound) resembles {v} (Compound)",
"Tripelennamine"
]
],
[
[
"Dexbrompheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Dimetindene"
],
[
"Dimetindene",
"{u} (Compound) resembles {v} (Compound)",
"Tripelennamine"
]
],
[
[
"Dexbrompheniramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tripelennamine"
]
],
[
[
"Dexbrompheniramine",
"{u} (Compound) binds {v} (Gene)",
"HRH1"
],
[
"HRH1",
"{u} (Gene) is bound by {v} (Compound)",
"Tripelennamine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tripelennamine"
]
]
] |
Dexbrompheniramine (Compound) resembles Chloropyramine (Compound) and Chloropyramine (Compound) resembles Tripelennamine (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Tripelennamine (Compound)
Dexbrompheniramine (Compound) resembles Doxylamine (Compound) and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Dexbrompheniramine (Compound) resembles Bromodiphenhydramine (Compound) and Bromodiphenhydramine (Compound) resembles Tripelennamine (Compound)
Dexbrompheniramine (Compound) resembles Dimetindene (Compound) and Dimetindene (Compound) resembles Tripelennamine (Compound)
Dexbrompheniramine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Tripelennamine
Dexbrompheniramine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Tripelennamine (Compound)
Dexbrompheniramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Tripelennamine
|
DB00322
|
DB01059
| 141
| 956
|
[
"DDInter742",
"DDInter1313"
] |
Floxuridine
|
Norfloxacin
|
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
|
A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.
|
Minor
| 0
|
[
[
[
141,
23,
956
]
],
[
[
141,
23,
872
],
[
872,
40,
956
]
],
[
[
141,
62,
1176
],
[
1176,
1,
956
]
],
[
[
141,
23,
1539
],
[
1539,
1,
956
]
],
[
[
141,
18,
3199
],
[
3199,
45,
956
]
],
[
[
141,
18,
2201
],
[
2201,
57,
956
]
],
[
[
141,
21,
29104
],
[
29104,
60,
956
]
],
[
[
141,
24,
1307
],
[
1307,
23,
956
]
],
[
[
141,
63,
377
],
[
377,
23,
956
]
],
[
[
141,
24,
1532
],
[
1532,
62,
956
]
]
] |
[
[
[
"Floxuridine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
],
[
[
"Floxuridine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Floxuridine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Floxuridine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Floxuridine",
"{u} (Compound) downregulates {v} (Gene)",
"TOP2A"
],
[
"TOP2A",
"{u} (Gene) is bound by {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Floxuridine",
"{u} (Compound) downregulates {v} (Gene)",
"PPP2R5E"
],
[
"PPP2R5E",
"{u} (Gene) is downregulated by {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Floxuridine",
"{u} (Compound) causes {v} (Side Effect)",
"Nystagmus"
],
[
"Nystagmus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
],
[
"Melphalan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
],
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mitomycin"
],
[
"Mitomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
],
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
]
] |
Floxuridine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Floxuridine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (Compound)
Floxuridine may cause a minor interaction that can limit clinical effects when taken with Ofloxacin and Ofloxacin (Compound) resembles Norfloxacin (Compound)
Floxuridine (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Norfloxacin (Compound)
Floxuridine (Compound) downregulates PPP2R5E (Gene) and PPP2R5E (Gene) is downregulated by Norfloxacin (Compound)
Floxuridine (Compound) causes Nystagmus (Side Effect) and Nystagmus (Side Effect) is caused by Norfloxacin (Compound)
Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan may cause a minor interaction that can limit clinical effects when taken with Norfloxacin
Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin may cause a minor interaction that can limit clinical effects when taken with Norfloxacin
Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a minor interaction that can limit clinical effects when taken with Norfloxacin
|
DB00598
|
DB01362
| 1,523
| 497
|
[
"DDInter1013",
"DDInter960"
] |
Labetalol
|
Iohexol
|
Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.
|
Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
|
Moderate
| 1
|
[
[
[
1523,
24,
497
]
],
[
[
1523,
24,
258
],
[
258,
40,
497
]
],
[
[
1523,
21,
28681
],
[
28681,
60,
497
]
],
[
[
1523,
24,
1013
],
[
1013,
63,
497
]
],
[
[
1523,
63,
999
],
[
999,
25,
497
]
],
[
[
1523,
24,
891
],
[
891,
25,
497
]
],
[
[
1523,
24,
22
],
[
22,
64,
497
]
],
[
[
1523,
40,
935
],
[
935,
25,
497
]
],
[
[
1523,
37,
247
],
[
247,
64,
497
]
],
[
[
1523,
64,
1031
],
[
1031,
25,
497
]
]
] |
[
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
],
[
"Iodixanol",
"{u} (Compound) resembles {v} (Compound)",
"Iohexol"
]
],
[
[
"Labetalol",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iohexol"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tyropanoic acid"
],
[
"Tyropanoic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Labetalol",
"{u} (Compound) resembles {v} (Compound)",
"Ketoprofen"
],
[
"Ketoprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
],
[
"Iobenguane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Labetalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
]
] |
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol and Iodixanol (Compound) resembles Iohexol (Compound)
Labetalol (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid and Tyropanoic acid may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may lead to a major life threatening interaction when taken with Iohexol
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may lead to a major life threatening interaction when taken with Iohexol
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may lead to a major life threatening interaction when taken with Iohexol
Labetalol (Compound) resembles Ketoprofen (Compound) and Ketoprofen may lead to a major life threatening interaction when taken with Iohexol
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Labetalol may lead to a major life threatening interaction when taken with Iobenguane and Iobenguane may lead to a major life threatening interaction when taken with Iohexol
Labetalol may lead to a major life threatening interaction when taken with Theophylline and Theophylline may lead to a major life threatening interaction when taken with Iohexol
|
DB00580
|
DB00912
| 311
| 473
|
[
"DDInter1910",
"DDInter1581"
] |
Valdecoxib
|
Repaglinide
|
Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
|
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Repaglinide is extensively metabolized in the liver and excreted in bile. Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine.
|
Moderate
| 1
|
[
[
[
311,
24,
473
]
],
[
[
311,
24,
609
],
[
609,
63,
473
]
],
[
[
311,
24,
1512
],
[
1512,
24,
473
]
],
[
[
311,
63,
1645
],
[
1645,
24,
473
]
],
[
[
311,
25,
1510
],
[
1510,
63,
473
]
],
[
[
311,
25,
629
],
[
629,
24,
473
]
],
[
[
311,
24,
1347
],
[
1347,
25,
473
]
],
[
[
311,
24,
609
],
[
609,
6,
8374
],
[
8374,
45,
473
]
],
[
[
311,
63,
1645
],
[
1645,
5,
11640
],
[
11640,
44,
473
]
],
[
[
311,
24,
351
],
[
351,
64,
798
],
[
798,
24,
473
]
]
] |
[
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Valdecoxib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Valdecoxib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Repaglinide"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Repaglinide"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} (Compound) treats {v} (Disease)",
"type 2 diabetes mellitus"
],
[
"type 2 diabetes mellitus",
"{u} (Disease) is treated by {v} (Compound)",
"Repaglinide"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
]
] |
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Valdecoxib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Valdecoxib may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Repaglinide
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Repaglinide (Compound)
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Repaglinide (Compound)
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Nelfinavir and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
|
DB01042
|
DB05273
| 1,307
| 507
|
[
"DDInter1144",
"DDInter1638"
] |
Melphalan
|
Samarium (153Sm) lexidronam
|
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
|
Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help relieve the bone pain that may occur with certain kinds of cancer. The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain.
|
Major
| 2
|
[
[
[
1307,
25,
507
]
],
[
[
1307,
24,
248
],
[
248,
24,
507
]
],
[
[
1307,
63,
563
],
[
563,
24,
507
]
],
[
[
1307,
24,
270
],
[
270,
63,
507
]
],
[
[
1307,
63,
970
],
[
970,
25,
507
]
],
[
[
1307,
24,
77
],
[
77,
25,
507
]
],
[
[
1307,
64,
1064
],
[
1064,
25,
507
]
],
[
[
1307,
24,
1330
],
[
1330,
64,
507
]
],
[
[
1307,
62,
168
],
[
168,
25,
507
]
],
[
[
1307,
25,
1259
],
[
1259,
64,
507
]
]
] |
[
[
[
"Melphalan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
],
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Melphalan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
],
[
"Naxitamab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Melphalan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Melphalan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
]
] |
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil and Fluorouracil may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Melphalan may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab and Naxitamab may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Melphalan may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Melphalan may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
|
DB00445
|
DB06626
| 322
| 263
|
[
"DDInter655",
"DDInter147"
] |
Epirubicin
|
Axitinib
|
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
|
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors. Axitinib is an indazole derivative. It is most commonly marketed under the name Inlyta® and is available in oral formulations.
|
Moderate
| 1
|
[
[
[
322,
24,
263
]
],
[
[
322,
25,
752
],
[
752,
23,
263
]
],
[
[
322,
24,
1559
],
[
1559,
23,
263
]
],
[
[
322,
64,
702
],
[
702,
24,
263
]
],
[
[
322,
24,
392
],
[
392,
24,
263
]
],
[
[
322,
25,
1593
],
[
1593,
63,
263
]
],
[
[
322,
25,
33
],
[
33,
24,
263
]
],
[
[
322,
24,
1613
],
[
1613,
63,
263
]
],
[
[
322,
63,
482
],
[
482,
24,
263
]
],
[
[
322,
63,
362
],
[
362,
25,
263
]
]
] |
[
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Axitinib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Axitinib"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
]
]
] |
Epirubicin may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Axitinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a minor interaction that can limit clinical effects when taken with Axitinib
Epirubicin may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Epirubicin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Epirubicin may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may lead to a major life threatening interaction when taken with Axitinib
|
DB00023
|
DB00795
| 305
| 50
|
[
"DDInter127",
"DDInter1725"
] |
Asparaginase Escherichia coli
|
Sulfasalazine
|
Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997]. L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from _E. coli_ works by depleting the levels
|
Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970. Although sulfasalazine is only approved by the FDA for ulcerative colitis, research have shown that sulfasalazine is also beneficial for patients with Crohn's disease. Meta-analysis of 19 randomized controlled trials indicated that sulfasalazine is superior to placebo in inducing remission; however, with no supported evidence of mucosal healing, sulfasalazine is not FDA-recommmended for treatment of Crohn's disease.[A255597,A255602,A255607]
|
Moderate
| 1
|
[
[
[
305,
24,
50
]
],
[
[
305,
24,
161
],
[
161,
1,
50
]
],
[
[
305,
24,
1144
],
[
1144,
24,
50
]
],
[
[
305,
24,
998
],
[
998,
63,
50
]
],
[
[
305,
25,
990
],
[
990,
64,
50
]
],
[
[
305,
24,
279
],
[
279,
64,
50
]
],
[
[
305,
24,
126
],
[
126,
25,
50
]
],
[
[
305,
24,
161
],
[
161,
1,
11249
],
[
11249,
1,
50
]
],
[
[
305,
24,
1144
],
[
1144,
24,
712
],
[
712,
1,
50
]
],
[
[
305,
24,
267
],
[
267,
63,
161
],
[
161,
1,
50
]
]
] |
[
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfasalazine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
],
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfaphenazole"
],
[
"Sulfaphenazole",
"{u} (Compound) resembles {v} (Compound)",
"Sulfasalazine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfasalazine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfasalazine"
]
]
] |
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembles Sulfasalazine (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Sulfasalazine
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may lead to a major life threatening interaction when taken with Sulfasalazine
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Sulfasalazine
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembles Sulfaphenazole (Compound) and Sulfaphenazole (Compound) resembles Sulfasalazine (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine (Compound) resembles Sulfasalazine (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembles Sulfasalazine (Compound)
|
DB01044
|
DB13142
| 246
| 841
|
[
"DDInter809",
"DDInter274"
] |
Gatifloxacin
|
Calcium glubionate anhydrous
|
Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.[L43942,L44037]
|
Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets.
|
Moderate
| 1
|
[
[
[
246,
24,
841
]
],
[
[
246,
1,
945
],
[
945,
24,
841
]
],
[
[
246,
40,
1176
],
[
1176,
24,
841
]
],
[
[
246,
1,
945
],
[
945,
40,
1539
],
[
1539,
24,
841
]
],
[
[
246,
1,
1539
],
[
1539,
1,
945
],
[
945,
24,
841
]
],
[
[
246,
40,
1176
],
[
1176,
1,
945
],
[
945,
24,
841
]
],
[
[
246,
62,
196
],
[
196,
23,
255
],
[
255,
24,
841
]
],
[
[
246,
62,
196
],
[
196,
25,
1292
],
[
1292,
24,
841
]
],
[
[
246,
40,
739
],
[
739,
40,
1176
],
[
1176,
24,
841
]
],
[
[
246,
62,
196
],
[
196,
24,
810
],
[
810,
24,
841
]
]
] |
[
[
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Altretamine"
],
[
"Altretamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Altretamine"
],
[
"Altretamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Altretamine"
],
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
],
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
]
] |
Gatifloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Gatifloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Gatifloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Gatifloxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Gatifloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Altretamine and Altretamine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Altretamine and Altretamine may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Gatifloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Altretamine and Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
|
DB00603
|
DB08820
| 303
| 1,478
|
[
"DDInter1137",
"DDInter997"
] |
Medroxyprogesterone acetate
|
Ivacaftor
|
Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma.[L8657,L8660,L8663,L8666,L8669] Medroxyprogesterone acetate was granted FDA approval on 18 June 1959.
|
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms.
|
Moderate
| 1
|
[
[
[
303,
24,
1478
]
],
[
[
303,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
303,
21,
29221
],
[
29221,
60,
1478
]
],
[
[
303,
24,
307
],
[
307,
23,
1478
]
],
[
[
303,
24,
1411
],
[
1411,
24,
1478
]
],
[
[
303,
63,
245
],
[
245,
24,
1478
]
],
[
[
303,
25,
1040
],
[
1040,
63,
1478
]
],
[
[
303,
24,
484
],
[
484,
63,
1478
]
],
[
[
303,
64,
152
],
[
152,
24,
1478
]
],
[
[
303,
23,
888
],
[
888,
24,
1478
]
]
] |
[
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ivacaftor"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation"
],
[
"Infestation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ivacaftor"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivacaftor"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosentan"
],
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
]
] |
Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Medroxyprogesterone acetate (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Ivacaftor (Compound)
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Medroxyprogesterone acetate may lead to a major life threatening interaction when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Medroxyprogesterone acetate may lead to a major life threatening interaction when taken with Bosentan and Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Medroxyprogesterone acetate may cause a minor interaction that can limit clinical effects when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
|
DB01222
|
DB08820
| 617
| 1,478
|
[
"DDInter246",
"DDInter997"
] |
Budesonide
|
Ivacaftor
|
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with [formoterol].
|
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms.
|
Moderate
| 1
|
[
[
[
617,
24,
1478
]
],
[
[
617,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
617,
21,
29221
],
[
29221,
60,
1478
]
],
[
[
617,
24,
1586
],
[
1586,
63,
1478
]
],
[
[
617,
40,
891
],
[
891,
24,
1478
]
],
[
[
617,
63,
380
],
[
380,
24,
1478
]
],
[
[
617,
24,
984
],
[
984,
24,
1478
]
],
[
[
617,
64,
932
],
[
932,
24,
1478
]
],
[
[
617,
63,
600
],
[
600,
25,
1478
]
],
[
[
617,
24,
1593
],
[
1593,
64,
1478
]
]
] |
[
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Budesonide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ivacaftor"
]
],
[
[
"Budesonide",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation"
],
[
"Infestation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ivacaftor"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
],
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conjugated estrogens"
],
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danazol"
],
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
]
]
] |
Budesonide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Budesonide (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Ivacaftor (Compound)
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine and Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Budesonide (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Danazol and Danazol may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Budesonide may lead to a major life threatening interaction when taken with Mifepristone and Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ivacaftor
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Ivacaftor
|
DB06605
|
DB09118
| 1,409
| 1,580
|
[
"DDInter108",
"DDInter1711"
] |
Apixaban
|
Stiripentol
|
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012.
|
Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes. However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs, hence boosting their therapeutic efficacy. Stiripentol may also exhibit direct anticonvulsant properties, although the exact mechanism of action is fully understood. Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit.
|
Moderate
| 1
|
[
[
[
1409,
24,
1580
]
],
[
[
1409,
24,
283
],
[
283,
63,
1580
]
],
[
[
1409,
64,
1018
],
[
1018,
24,
1580
]
],
[
[
1409,
24,
98
],
[
98,
24,
1580
]
],
[
[
1409,
63,
79
],
[
79,
24,
1580
]
],
[
[
1409,
25,
1468
],
[
1468,
24,
1580
]
],
[
[
1409,
24,
1456
],
[
1456,
64,
1580
]
],
[
[
1409,
64,
477
],
[
477,
25,
1580
]
],
[
[
1409,
25,
405
],
[
405,
64,
1580
]
],
[
[
1409,
25,
129
],
[
129,
25,
1580
]
]
] |
[
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
]
]
] |
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Apixaban may lead to a major life threatening interaction when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Apixaban may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may lead to a major life threatening interaction when taken with Stiripentol
Apixaban may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol may lead to a major life threatening interaction when taken with Stiripentol
Apixaban may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may lead to a major life threatening interaction when taken with Stiripentol
Apixaban may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Stiripentol
|
DB00314
|
DB00741
| 894
| 167
|
[
"DDInter288",
"DDInter885"
] |
Capreomycin
|
Hydrocortisone
|
Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus.
|
Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952.
|
Moderate
| 1
|
[
[
[
894,
24,
167
]
],
[
[
894,
24,
1220
],
[
1220,
40,
167
]
],
[
[
894,
24,
870
],
[
870,
1,
167
]
],
[
[
894,
21,
28680
],
[
28680,
60,
167
]
],
[
[
894,
25,
629
],
[
629,
63,
167
]
],
[
[
894,
24,
589
],
[
589,
24,
167
]
],
[
[
894,
24,
123
],
[
123,
63,
167
]
],
[
[
894,
25,
497
],
[
497,
64,
167
]
],
[
[
894,
24,
1220
],
[
1220,
1,
1343
],
[
1343,
40,
167
]
],
[
[
894,
24,
175
],
[
175,
40,
1343
],
[
1343,
40,
167
]
]
] |
[
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
]
],
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
]
],
[
[
"Capreomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydrocortisone"
]
],
[
[
"Capreomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Capreomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Loteprednol"
],
[
"Loteprednol",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
]
],
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Loteprednol"
],
[
"Loteprednol",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
]
]
] |
Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Hydrocortisone (Compound)
Capreomycin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Hydrocortisone (Compound)
Capreomycin may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Capreomycin may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Hydrocortisone
Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Loteprednol (Compound) and Loteprednol (Compound) resembles Hydrocortisone (Compound)
Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Loteprednol (Compound) and Loteprednol (Compound) resembles Hydrocortisone (Compound)
|
DB00692
|
DB00902
| 274
| 104
|
[
"DDInter1448",
"DDInter1168"
] |
Phentolamine
|
Methdilazine
|
Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[A261781, A261786] It has several therapeutic uses, including the treatment of hypertensive episodes, prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue anesthesia, and treatment of pharmacologically-induced mydriasis.[L48420, L48415, L48390] Phentolamine is administered intravenously, intramuscularly, submucosally, and topically.
|
Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus.
|
Moderate
| 1
|
[
[
[
274,
24,
104
]
],
[
[
274,
24,
820
],
[
820,
1,
104
]
],
[
[
274,
63,
508
],
[
508,
1,
104
]
],
[
[
274,
24,
401
],
[
401,
63,
104
]
],
[
[
274,
63,
1216
],
[
1216,
24,
104
]
],
[
[
274,
23,
1296
],
[
1296,
63,
104
]
],
[
[
274,
62,
1179
],
[
1179,
24,
104
]
],
[
[
274,
24,
1664
],
[
1664,
24,
104
]
],
[
[
274,
25,
876
],
[
876,
24,
104
]
],
[
[
274,
63,
675
],
[
675,
25,
104
]
]
] |
[
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Phentolamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Phentolamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Phentolamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methdilazine"
]
]
] |
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Methdilazine (Compound)
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Phentolamine may lead to a major life threatening interaction when taken with Tizanidine and Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Methdilazine
|
DB00283
|
DB00575
| 701
| 1,020
|
[
"DDInter395",
"DDInter412"
] |
Clemastine
|
Clonidine
|
An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
|
Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974.
|
Moderate
| 1
|
[
[
[
701,
24,
1020
]
],
[
[
701,
24,
1617
],
[
1617,
40,
1020
]
],
[
[
701,
6,
8374
],
[
8374,
45,
1020
]
],
[
[
701,
21,
28762
],
[
28762,
60,
1020
]
],
[
[
701,
24,
1311
],
[
1311,
63,
1020
]
],
[
[
701,
24,
128
],
[
128,
24,
1020
]
],
[
[
701,
35,
1594
],
[
1594,
24,
1020
]
],
[
[
701,
24,
1264
],
[
1264,
64,
1020
]
],
[
[
701,
24,
1617
],
[
1617,
1,
1084
],
[
1084,
40,
1020
]
],
[
[
701,
24,
1084
],
[
1084,
40,
1617
],
[
1617,
40,
1020
]
]
] |
[
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
],
[
"Apraclonidine",
"{u} (Compound) resembles {v} (Compound)",
"Clonidine"
]
],
[
[
"Clemastine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Clonidine"
]
],
[
[
"Clemastine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clonidine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clonidine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
],
[
"Apraclonidine",
"{u} (Compound) resembles {v} (Compound)",
"Lofexidine"
],
[
"Lofexidine",
"{u} (Compound) resembles {v} (Compound)",
"Clonidine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
],
[
"Lofexidine",
"{u} (Compound) resembles {v} (Compound)",
"Apraclonidine"
],
[
"Apraclonidine",
"{u} (Compound) resembles {v} (Compound)",
"Clonidine"
]
]
] |
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Apraclonidine and Apraclonidine (Compound) resembles Clonidine (Compound)
Clemastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clonidine (Compound)
Clemastine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Clonidine (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Clonidine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine
Clemastine (Compound) resembles Doxylamine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Clonidine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Apraclonidine and Apraclonidine (Compound) resembles Lofexidine (Compound) and Lofexidine (Compound) resembles Clonidine (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine and Lofexidine (Compound) resembles Apraclonidine (Compound) and Apraclonidine (Compound) resembles Clonidine (Compound)
|
DB01602
|
DB06723
| 339
| 115
|
[
"DDInter159",
"DDInter58"
] |
Bacampicillin
|
Aluminum hydroxide
|
Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal action through the inhibition of the biosynthesis of cell wall mucopeptides. It is used to cure infection of upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis etc.
|
Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects.
|
Moderate
| 1
|
[
[
[
339,
24,
115
]
],
[
[
339,
63,
1194
],
[
1194,
23,
115
]
],
[
[
339,
1,
1305
],
[
1305,
24,
115
]
],
[
[
339,
63,
1096
],
[
1096,
24,
115
]
],
[
[
339,
24,
1475
],
[
1475,
64,
115
]
],
[
[
339,
63,
1194
],
[
1194,
21,
28882
],
[
28882,
60,
115
]
],
[
[
339,
1,
1305
],
[
1305,
21,
28845
],
[
28845,
60,
115
]
],
[
[
339,
63,
1620
],
[
1620,
24,
1482
],
[
1482,
23,
115
]
],
[
[
339,
1,
11253
],
[
11253,
40,
1305
],
[
1305,
24,
115
]
],
[
[
339,
24,
1475
],
[
1475,
62,
1058
],
[
1058,
23,
115
]
]
] |
[
[
[
"Bacampicillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Bacampicillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Bacampicillin",
"{u} (Compound) resembles {v} (Compound)",
"Cefaclor"
],
[
"Cefaclor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Bacampicillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Bacampicillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
],
[
"Sodium citrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Bacampicillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aluminum hydroxide"
]
],
[
[
"Bacampicillin",
"{u} (Compound) resembles {v} (Compound)",
"Cefaclor"
],
[
"Cefaclor",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema"
],
[
"Oedema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aluminum hydroxide"
]
],
[
[
"Bacampicillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
],
[
"Digitoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Bacampicillin",
"{u} (Compound) resembles {v} (Compound)",
"Azlocillin"
],
[
"Azlocillin",
"{u} (Compound) resembles {v} (Compound)",
"Cefaclor"
],
[
"Cefaclor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Bacampicillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
],
[
"Sodium citrate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moexipril"
],
[
"Moexipril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
]
] |
Bacampicillin may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Bacampicillin (Compound) resembles Cefaclor (Compound) and Cefaclor may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide
Bacampicillin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide
Bacampicillin may cause a moderate interaction that could exacerbate diseases when taken with Sodium citrate and Sodium citrate may lead to a major life threatening interaction when taken with Aluminum hydroxide
Bacampicillin may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Aluminum hydroxide (Compound)
Bacampicillin (Compound) resembles Cefaclor (Compound) and Cefaclor (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Aluminum hydroxide (Compound)
Bacampicillin may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Bacampicillin (Compound) resembles Azlocillin (Compound) and Azlocillin (Compound) resembles Cefaclor (Compound) and Cefaclor may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide
Bacampicillin may cause a moderate interaction that could exacerbate diseases when taken with Sodium citrate and Sodium citrate may cause a minor interaction that can limit clinical effects when taken with Moexipril and Moexipril may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
|
DB00158
|
DB00776
| 356
| 1,335
|
[
"DDInter771",
"DDInter1360"
] |
Folic acid
|
Oxcarbazepine
|
Folic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis. More specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. Folic acid is particularly important during phases of rapid cell division, such as infancy, pregnancy, and erythropoiesis, and plays a protective factor in the development of cancer. As humans are unable to synthesize folic acid endogenously, diet and supplementation is necessary to prevent deficiencies. For example, folic acid is present in green vegetables, beans, avocado, and some fruits. In order to function within the body, folic acid must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (TH
|
Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood - a pro-drug of the more active (S)-enantiomer is also marketed as a separate anti-epileptic under the name [eslicarbazepine]. Compared to other anti-epileptic drugs, which are generally metabolized via the cytochrome P450 system, oxcarbazepine has a reduced propensity for involvement in drug-drug interactions owing to its primarily reductive metabolism.
|
Moderate
| 1
|
[
[
[
356,
24,
1335
]
],
[
[
356,
24,
1236
],
[
1236,
1,
1335
]
],
[
[
356,
21,
28701
],
[
28701,
60,
1335
]
],
[
[
356,
1,
1147
],
[
1147,
24,
1335
]
],
[
[
356,
24,
1236
],
[
1236,
1,
11346
],
[
11346,
1,
1335
]
],
[
[
356,
21,
28701
],
[
28701,
60,
1605
],
[
1605,
1,
1335
]
],
[
[
356,
21,
28751
],
[
28751,
60,
1264
],
[
1264,
63,
1335
]
],
[
[
356,
40,
11343
],
[
11343,
1,
1147
],
[
1147,
24,
1335
]
],
[
[
356,
1,
1147
],
[
1147,
63,
1236
],
[
1236,
1,
1335
]
],
[
[
356,
24,
1236
],
[
1236,
24,
126
],
[
126,
1,
1335
]
]
] |
[
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} (Compound) resembles {v} (Compound)",
"Oxcarbazepine"
]
],
[
[
"Folic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Discomfort"
],
[
"Discomfort",
"{u} (Side Effect) is caused by {v} (Compound)",
"Oxcarbazepine"
]
],
[
[
"Folic acid",
"{u} (Compound) resembles {v} (Compound)",
"Leucovorin"
],
[
"Leucovorin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} (Compound) resembles {v} (Compound)",
"Magnesium salicylate"
],
[
"Magnesium salicylate",
"{u} (Compound) resembles {v} (Compound)",
"Oxcarbazepine"
]
],
[
[
"Folic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Discomfort"
],
[
"Discomfort",
"{u} (Side Effect) is caused by {v} (Compound)",
"Indapamide"
],
[
"Indapamide",
"{u} (Compound) resembles {v} (Compound)",
"Oxcarbazepine"
]
],
[
[
"Folic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Folic acid",
"{u} (Compound) resembles {v} (Compound)",
"Tetrahydrofolic acid"
],
[
"Tetrahydrofolic acid",
"{u} (Compound) resembles {v} (Compound)",
"Leucovorin"
],
[
"Leucovorin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Folic acid",
"{u} (Compound) resembles {v} (Compound)",
"Leucovorin"
],
[
"Leucovorin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} (Compound) resembles {v} (Compound)",
"Oxcarbazepine"
]
],
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} (Compound) resembles {v} (Compound)",
"Oxcarbazepine"
]
]
] |
Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine (Compound) resembles Oxcarbazepine (Compound)
Folic acid (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Oxcarbazepine (Compound)
Folic acid (Compound) resembles Leucovorin (Compound) and Leucovorin may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine
Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine (Compound) resembles Magnesium salicylate (Compound) and Magnesium salicylate (Compound) resembles Oxcarbazepine (Compound)
Folic acid (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Indapamide (Compound) and Indapamide (Compound) resembles Oxcarbazepine (Compound)
Folic acid (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Doxepin (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine
Folic acid (Compound) resembles Tetrahydrofolic acid (Compound) and Tetrahydrofolic acid (Compound) resembles Leucovorin (Compound) and Leucovorin may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine
Folic acid (Compound) resembles Leucovorin (Compound) and Leucovorin may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine (Compound) resembles Oxcarbazepine (Compound)
Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Oxcarbazepine (Compound)
|
DB01006
|
DB01174
| 300
| 697
|
[
"DDInter1040",
"DDInter1442"
] |
Letrozole
|
Phenobarbital
|
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole was granted FDA approval on 25 July 1997.
|
A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
|
Minor
| 0
|
[
[
[
300,
23,
697
]
],
[
[
300,
6,
8717
],
[
8717,
45,
697
]
],
[
[
300,
21,
28905
],
[
28905,
60,
697
]
],
[
[
300,
63,
1101
],
[
1101,
23,
697
]
],
[
[
300,
24,
129
],
[
129,
63,
697
]
],
[
[
300,
25,
770
],
[
770,
24,
697
]
],
[
[
300,
63,
723
],
[
723,
24,
697
]
],
[
[
300,
24,
159
],
[
159,
64,
697
]
],
[
[
300,
63,
629
],
[
629,
25,
697
]
],
[
[
300,
6,
8717
],
[
8717,
45,
773
],
[
773,
1,
697
]
]
] |
[
[
[
"Letrozole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenobarbital"
]
],
[
[
"Letrozole",
"{u} (Compound) binds {v} (Gene)",
"CYP2A6"
],
[
"CYP2A6",
"{u} (Gene) is bound by {v} (Compound)",
"Phenobarbital"
]
],
[
[
"Letrozole",
"{u} (Compound) causes {v} (Side Effect)",
"Irritability"
],
[
"Irritability",
"{u} (Side Effect) is caused by {v} (Compound)",
"Phenobarbital"
]
],
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenobarbital"
]
],
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Letrozole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenobarbital"
]
],
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenobarbital"
]
],
[
[
"Letrozole",
"{u} (Compound) binds {v} (Gene)",
"CYP2A6"
],
[
"CYP2A6",
"{u} (Gene) is bound by {v} (Compound)",
"Amobarbital"
],
[
"Amobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
]
]
] |
Letrozole (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Phenobarbital (Compound)
Letrozole (Compound) causes Irritability (Side Effect) and Irritability (Side Effect) is caused by Phenobarbital (Compound)
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Phenobarbital
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital
Letrozole may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may lead to a major life threatening interaction when taken with Phenobarbital
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Phenobarbital
Letrozole (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Amobarbital (Compound) and Amobarbital (Compound) resembles Phenobarbital (Compound)
|
DB06448
|
DB06616
| 171
| 594
|
[
"DDInter1087",
"DDInter224"
] |
Lonafarnib
|
Bosutinib
|
Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.[A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FT
|
Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR ABL ratio on an international scale, with bosutinib treatment.
|
Major
| 2
|
[
[
[
171,
25,
594
]
],
[
[
171,
63,
883
],
[
883,
1,
594
]
],
[
[
171,
63,
112
],
[
112,
23,
594
]
],
[
[
171,
63,
1215
],
[
1215,
24,
594
]
],
[
[
171,
25,
1040
],
[
1040,
63,
594
]
],
[
[
171,
64,
597
],
[
597,
24,
594
]
],
[
[
171,
25,
1250
],
[
1250,
24,
594
]
],
[
[
171,
24,
738
],
[
738,
63,
594
]
],
[
[
171,
25,
985
],
[
985,
64,
594
]
],
[
[
171,
64,
1493
],
[
1493,
25,
594
]
]
] |
[
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Bosutinib"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bosutinib"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
],
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
]
] |
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Bosutinib (Compound)
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bosutinib
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Lonafarnib may lead to a major life threatening interaction when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Lonafarnib may lead to a major life threatening interaction when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Lonafarnib may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Lonafarnib may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Bosutinib
Lonafarnib may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may lead to a major life threatening interaction when taken with Bosutinib
|
DB00250
|
DB01045
| 10
| 463
|
[
"DDInter475",
"DDInter1590"
] |
Dapsone
|
Rifampicin
|
A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)
|
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
|
Moderate
| 1
|
[
[
[
10,
24,
463
]
],
[
[
10,
24,
690
],
[
690,
40,
463
]
],
[
[
10,
5,
11654
],
[
11654,
44,
463
]
],
[
[
10,
6,
10215
],
[
10215,
45,
463
]
],
[
[
10,
24,
1468
],
[
1468,
63,
463
]
],
[
[
10,
24,
597
],
[
597,
24,
463
]
],
[
[
10,
64,
1064
],
[
1064,
24,
463
]
],
[
[
10,
24,
1424
],
[
1424,
25,
463
]
],
[
[
10,
24,
1480
],
[
1480,
64,
463
]
],
[
[
10,
63,
168
],
[
168,
25,
463
]
]
] |
[
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],
[
"Rifabutin",
"{u} (Compound) resembles {v} (Compound)",
"Rifampicin"
]
],
[
[
"Dapsone",
"{u} (Compound) treats {v} (Disease)",
"leprosy"
],
[
"leprosy",
"{u} (Disease) is treated by {v} (Compound)",
"Rifampicin"
]
],
[
[
"Dapsone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Rifampicin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Dapsone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifampicin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifampicin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifampicin"
]
]
] |
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound)
Dapsone (Compound) treats leprosy (Disease) and leprosy (Disease) is treated by Rifampicin (Compound)
Dapsone (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Rifampicin (Compound)
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Dapsone may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may lead to a major life threatening interaction when taken with Rifampicin
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may lead to a major life threatening interaction when taken with Rifampicin
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may lead to a major life threatening interaction when taken with Rifampicin
|
DB06754
|
DB09079
| 707
| 1,496
|
[
"DDInter471",
"DDInter1296"
] |
Danaparoid
|
Nintedanib
|
Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans. The active constituents are heparan, dermatan and, and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting activated factor X (Factor Xa) and activated factor II (Factor IIa). It is chemically distinct from heparin by containing different protein binding properties, thus has lower cross-reactivity in heparin-intolerant patients. Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and prevention of post-operative deep venous thrombosis (DVT). While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August
|
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function. As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.
|
Moderate
| 1
|
[
[
[
707,
24,
1496
]
],
[
[
707,
64,
20
],
[
20,
24,
1496
]
],
[
[
707,
25,
365
],
[
365,
24,
1496
]
],
[
[
707,
24,
1412
],
[
1412,
63,
1496
]
],
[
[
707,
63,
305
],
[
305,
24,
1496
]
],
[
[
707,
25,
235
],
[
235,
63,
1496
]
],
[
[
707,
24,
637
],
[
637,
24,
1496
]
],
[
[
707,
64,
834
],
[
834,
25,
1496
]
],
[
[
707,
64,
20
],
[
20,
24,
1317
],
[
1317,
24,
1496
]
],
[
[
707,
64,
1317
],
[
1317,
63,
20
],
[
20,
24,
1496
]
]
] |
[
[
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Danaparoid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Danaparoid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
],
[
"Dalteparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
],
[
"Calaspargase pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Danaparoid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
],
[
"Asparaginase Erwinia chrysanthemi",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Danaparoid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Drotrecogin alfa"
],
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nintedanib"
]
],
[
[
"Danaparoid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
],
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Danaparoid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dipyridamole"
],
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
]
] |
Danaparoid may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Danaparoid may lead to a major life threatening interaction when taken with Dalteparin and Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Danaparoid may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Danaparoid may lead to a major life threatening interaction when taken with Drotrecogin alfa and Drotrecogin alfa may lead to a major life threatening interaction when taken with Nintedanib
Danaparoid may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole and Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Danaparoid may lead to a major life threatening interaction when taken with Dipyridamole and Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
|
DB01050
|
DB01249
| 848
| 258
|
[
"DDInter900",
"DDInter958"
] |
Ibuprofen
|
Iodixanol
|
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID. On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than
|
Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents.
|
Major
| 2
|
[
[
[
848,
25,
258
]
],
[
[
848,
25,
497
],
[
497,
1,
258
]
],
[
[
848,
21,
28748
],
[
28748,
60,
258
]
],
[
[
848,
63,
443
],
[
443,
24,
258
]
],
[
[
848,
24,
178
],
[
178,
63,
258
]
],
[
[
848,
24,
699
],
[
699,
24,
258
]
],
[
[
848,
74,
17
],
[
17,
24,
258
]
],
[
[
848,
24,
712
],
[
712,
64,
258
]
],
[
[
848,
63,
1027
],
[
1027,
25,
258
]
],
[
[
848,
74,
1274
],
[
1274,
25,
258
]
]
] |
[
[
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
]
],
[
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} (Compound) resembles {v} (Compound)",
"Iodixanol"
]
],
[
[
"Ibuprofen",
"{u} (Compound) causes {v} (Side Effect)",
"Vertigo"
],
[
"Vertigo",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iodixanol"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Spironolactone"
],
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
],
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
],
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
]
],
[
[
"Ibuprofen",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
],
[
"Piroxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
]
],
[
[
"Ibuprofen",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
]
]
] |
Ibuprofen may lead to a major life threatening interaction when taken with Iohexol and Iohexol (Compound) resembles Iodixanol (Compound)
Ibuprofen (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Iodixanol (Compound)
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Spironolactone and Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol
Ibuprofen (Compound) resembles Sotalol (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may lead to a major life threatening interaction when taken with Iodixanol
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam may lead to a major life threatening interaction when taken with Iodixanol
Ibuprofen (Compound) resembles Flurbiprofen (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may lead to a major life threatening interaction when taken with Iodixanol
|
DB01097
|
DB14731
| 1,377
| 1,518
|
[
"DDInter1033",
"DDInter1741"
] |
Leflunomide
|
Tagraxofusp
|
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
|
Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is a myeloid malignancy in the dendritic cell lineage. It was also approved by the European Commission on January 7, 2021.
|
Major
| 2
|
[
[
[
1377,
25,
1518
]
],
[
[
1377,
64,
1324
],
[
1324,
24,
1518
]
],
[
[
1377,
24,
1411
],
[
1411,
24,
1518
]
],
[
[
1377,
25,
1130
],
[
1130,
24,
1518
]
],
[
[
1377,
63,
245
],
[
245,
24,
1518
]
],
[
[
1377,
24,
242
],
[
242,
63,
1518
]
],
[
[
1377,
25,
1070
],
[
1070,
25,
1518
]
],
[
[
1377,
64,
695
],
[
695,
25,
1518
]
],
[
[
1377,
64,
1324
],
[
1324,
63,
176
],
[
176,
24,
1518
]
],
[
[
1377,
24,
1411
],
[
1411,
24,
123
],
[
123,
24,
1518
]
]
] |
[
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pioglitazone"
],
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
],
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
]
] |
Leflunomide may lead to a major life threatening interaction when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Leflunomide may lead to a major life threatening interaction when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Leflunomide may lead to a major life threatening interaction when taken with Mipomersen and Mipomersen may lead to a major life threatening interaction when taken with Tagraxofusp
Leflunomide may lead to a major life threatening interaction when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Tagraxofusp
Leflunomide may lead to a major life threatening interaction when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
|
DB08899
|
DB11791
| 129
| 785
|
[
"DDInter649",
"DDInter287"
] |
Enzalutamide
|
Capmatinib
|
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile,
|
Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways such as STAT3, PI3K/ATK, and RAS/MAPK. Mutations in _MET_ have been detected in non-small cell lung cancer (NSCLC), and the prevalence of _MET_ amplification in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-naive patients with NSCLC has been reported to be 1.4% - 21%. This co-occurrence has made c-Met a desirable target in the treatment of NSCLC. Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020, for the treatment of NSCLC in patients whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same day. As this indication was granted under an accelerated approval, its continued approval is contingent upon verification of capmatinib's benefit in confirmatory trials. Capmatinib was approved by Health Canada on June 8, 2022.
|
Major
| 2
|
[
[
[
129,
25,
785
]
],
[
[
129,
63,
837
],
[
837,
23,
785
]
],
[
[
129,
25,
1135
],
[
1135,
23,
785
]
],
[
[
129,
63,
1324
],
[
1324,
24,
785
]
],
[
[
129,
64,
868
],
[
868,
24,
785
]
],
[
[
129,
24,
1320
],
[
1320,
63,
785
]
],
[
[
129,
24,
98
],
[
98,
24,
785
]
],
[
[
129,
25,
283
],
[
283,
63,
785
]
],
[
[
129,
25,
1362
],
[
1362,
24,
785
]
],
[
[
129,
62,
608
],
[
608,
24,
785
]
]
] |
[
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capmatinib"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capmatinib"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capmatinib"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
]
] |
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Enzalutamide may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Enzalutamide may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Enzalutamide may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Enzalutamide may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
|
DB00526
|
DB04844
| 1,555
| 843
|
[
"DDInter1355",
"DDInter1778"
] |
Oxaliplatin
|
Tetrabenazine
|
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The
|
A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.
|
Moderate
| 1
|
[
[
[
1555,
24,
843
]
],
[
[
1555,
24,
479
],
[
479,
40,
843
]
],
[
[
1555,
24,
112
],
[
112,
23,
843
]
],
[
[
1555,
63,
600
],
[
600,
24,
843
]
],
[
[
1555,
24,
286
],
[
286,
63,
843
]
],
[
[
1555,
24,
1559
],
[
1559,
24,
843
]
],
[
[
1555,
25,
351
],
[
351,
63,
843
]
],
[
[
1555,
25,
770
],
[
770,
24,
843
]
],
[
[
1555,
25,
985
],
[
985,
64,
843
]
],
[
[
1555,
24,
401
],
[
401,
25,
843
]
]
] |
[
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} (Compound) resembles {v} (Compound)",
"Tetrabenazine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetrabenazine"
]
]
] |
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Tetrabenazine
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
Oxaliplatin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
Oxaliplatin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
Oxaliplatin may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Tetrabenazine
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may lead to a major life threatening interaction when taken with Tetrabenazine
|
DB00331
|
DB00831
| 1,645
| 1,178
|
[
"DDInter1164",
"DDInter1866"
] |
Metformin
|
Trifluoperazine
|
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes. Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
|
A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.
|
Moderate
| 1
|
[
[
[
1645,
24,
1178
]
],
[
[
1645,
24,
695
],
[
695,
40,
1178
]
],
[
[
1645,
24,
9
],
[
9,
1,
1178
]
],
[
[
1645,
18,
5833
],
[
5833,
46,
1178
]
],
[
[
1645,
18,
20003
],
[
20003,
57,
1178
]
],
[
[
1645,
21,
29209
],
[
29209,
60,
1178
]
],
[
[
1645,
24,
417
],
[
417,
23,
1178
]
],
[
[
1645,
24,
1466
],
[
1466,
24,
1178
]
],
[
[
1645,
24,
1411
],
[
1411,
63,
1178
]
],
[
[
1645,
63,
245
],
[
245,
24,
1178
]
]
] |
[
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
],
[
"Methotrimeprazine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Metformin",
"{u} (Compound) downregulates {v} (Gene)",
"ACAT2"
],
[
"ACAT2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Metformin",
"{u} (Compound) downregulates {v} (Gene)",
"NOSIP"
],
[
"NOSIP",
"{u} (Gene) is downregulated by {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Metformin",
"{u} (Compound) causes {v} (Side Effect)",
"Anorexia"
],
[
"Anorexia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Trifluoperazine"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
],
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
]
] |
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Trifluoperazine (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine and Methotrimeprazine (Compound) resembles Trifluoperazine (Compound)
Metformin (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is upregulated by Trifluoperazine (Compound)
Metformin (Compound) downregulates NOSIP (Gene) and NOSIP (Gene) is downregulated by Trifluoperazine (Compound)
Metformin (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Trifluoperazine (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Trifluoperazine
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine
|
DB00687
|
DB00701
| 870
| 1,091
|
[
"DDInter747",
"DDInter90"
] |
Fludrocortisone
|
Amprenavir
|
Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency.
|
Amprenavir is a protease inhibitor used to treat HIV infection.
|
Moderate
| 1
|
[
[
[
870,
24,
1091
]
],
[
[
870,
24,
34
],
[
34,
1,
1091
]
],
[
[
870,
21,
28996
],
[
28996,
60,
1091
]
],
[
[
870,
63,
600
],
[
600,
23,
1091
]
],
[
[
870,
24,
609
],
[
609,
62,
1091
]
],
[
[
870,
23,
1283
],
[
1283,
63,
1091
]
],
[
[
870,
24,
52
],
[
52,
63,
1091
]
],
[
[
870,
63,
1101
],
[
1101,
24,
1091
]
],
[
[
870,
1,
891
],
[
891,
63,
1091
]
],
[
[
870,
1,
251
],
[
251,
24,
1091
]
]
] |
[
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
],
[
"Fosamprenavir",
"{u} (Compound) resembles {v} (Compound)",
"Amprenavir"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Musculoskeletal discomfort"
],
[
"Musculoskeletal discomfort",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amprenavir"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amprenavir"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amprenavir"
]
],
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
],
[
"Dulaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
]
]
] |
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and Fosamprenavir (Compound) resembles Amprenavir (Compound)
Fludrocortisone (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Amprenavir (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Amprenavir
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Amprenavir
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir
Fludrocortisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir
Fludrocortisone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir
|
DB01218
|
DB04844
| 1,493
| 843
|
[
"DDInter852",
"DDInter1778"
] |
Halofantrine
|
Tetrabenazine
|
Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.
|
A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.
|
Major
| 2
|
[
[
[
1493,
25,
843
]
],
[
[
1493,
62,
479
],
[
479,
40,
843
]
],
[
[
1493,
6,
12523
],
[
12523,
45,
843
]
],
[
[
1493,
21,
29093
],
[
29093,
60,
843
]
],
[
[
1493,
62,
112
],
[
112,
23,
843
]
],
[
[
1493,
64,
1555
],
[
1555,
24,
843
]
],
[
[
1493,
24,
286
],
[
286,
63,
843
]
],
[
[
1493,
25,
283
],
[
283,
63,
843
]
],
[
[
1493,
63,
1559
],
[
1559,
24,
843
]
],
[
[
1493,
25,
1213
],
[
1213,
24,
843
]
]
] |
[
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Halofantrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} (Compound) resembles {v} (Compound)",
"Tetrabenazine"
]
],
[
[
"Halofantrine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Tetrabenazine"
]
],
[
[
"Halofantrine",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tetrabenazine"
]
],
[
[
"Halofantrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Halofantrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Halofantrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
]
] |
Halofantrine may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Halofantrine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tetrabenazine (Compound)
Halofantrine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Tetrabenazine (Compound)
Halofantrine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Tetrabenazine
Halofantrine may lead to a major life threatening interaction when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
Halofantrine may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
Halofantrine may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
|
DB00674
|
DB01001
| 1,516
| 688
|
[
"DDInter802",
"DDInter1632"
] |
Galantamine
|
Salbutamol
|
Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as _Galanthus nivalis_. Galantamine was first studied in paralytic and neuropathic conditions, such as myopathies and postpolio paralytic conditions, and for reversal of neuromuscular blockade.[A182993,A201968] Following the discovery of its AChE-inhibiting properties, the cognitive effects of galantamine were studied in a wide variety of psychiatric disorders such as mild cognitive impairment, cognitive impairment in schizophrenia and bipolar disorder, and autism; however, re-development of the drug for Alzheimer’s disease did not commence until the early 1990s due to difficulties in extraction and
|
Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.[Label,A174379,A174400]
|
Moderate
| 1
|
[
[
[
1516,
24,
688
]
],
[
[
1516,
6,
8374
],
[
8374,
45,
688
]
],
[
[
1516,
21,
28714
],
[
28714,
60,
688
]
],
[
[
1516,
24,
112
],
[
112,
23,
688
]
],
[
[
1516,
24,
543
],
[
543,
24,
688
]
],
[
[
1516,
24,
1069
],
[
1069,
63,
688
]
],
[
[
1516,
63,
1010
],
[
1010,
24,
688
]
],
[
[
1516,
24,
351
],
[
351,
64,
688
]
],
[
[
1516,
6,
8374
],
[
8374,
45,
874
],
[
874,
24,
688
]
],
[
[
1516,
21,
28714
],
[
28714,
60,
454
],
[
454,
1,
688
]
]
] |
[
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Galantamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Salbutamol"
]
],
[
[
"Galantamine",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Salbutamol"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salbutamol"
]
],
[
[
"Galantamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Epinephrine"
],
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Galantamine",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Terbutaline"
],
[
"Terbutaline",
"{u} (Compound) resembles {v} (Compound)",
"Salbutamol"
]
]
] |
Galantamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salbutamol (Compound)
Galantamine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Salbutamol (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Salbutamol
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Salbutamol
Galantamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Epinephrine (Compound) and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Galantamine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Terbutaline (Compound) and Terbutaline (Compound) resembles Salbutamol (Compound)
|
DB00285
|
DB11095
| 1,100
| 235
|
[
"DDInter1927",
"DDInter505"
] |
Venlafaxine
|
Desirudin
|
Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder in adults. The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. Venlafaxine has been used as a first-line treatment for MDD, GAD, social anxiety disorder, and panic disorder in Canada for many years. It was also considered a second-line treatment for obsessive-compulsive disorder (OCD).[A177226,A177235] Venl
|
Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three disulfide bridges. Desirudin has a chemical formula of C287H440N80O110S6 with a molecular weight of 6963.52. It is mainly indicated for the prevention of deep vein thrombosis in hip replacement surgery patients. Common side effects include: Bleeding gums, collection of blood under the skin, coughing up blood, deep, dark purple bruise and difficulty with breathing or swallowing.
|
Moderate
| 1
|
[
[
[
1100,
24,
235
]
],
[
[
1100,
1,
643
],
[
643,
24,
235
]
],
[
[
1100,
24,
1151
],
[
1151,
24,
235
]
],
[
[
1100,
25,
121
],
[
121,
24,
235
]
],
[
[
1100,
24,
1409
],
[
1409,
25,
235
]
],
[
[
1100,
63,
1271
],
[
1271,
25,
235
]
],
[
[
1100,
24,
1421
],
[
1421,
64,
235
]
],
[
[
1100,
25,
39
],
[
39,
25,
235
]
],
[
[
1100,
64,
702
],
[
702,
25,
235
]
],
[
[
1100,
1,
643
],
[
643,
24,
578
],
[
578,
24,
235
]
]
] |
[
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Venlafaxine",
"{u} (Compound) resembles {v} (Compound)",
"Desvenlafaxine"
],
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alteplase"
],
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Venlafaxine",
"{u} (Compound) resembles {v} (Compound)",
"Desvenlafaxine"
],
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
]
] |
Venlafaxine (Compound) resembles Desvenlafaxine (Compound) and Des
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Venlafaxine may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Desirudin
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Alteplase and Alteplase may lead to a major life threatening interaction when taken with Desirudin
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may lead to a major life threatening interaction when taken with Desirudin
Venlafaxine may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Desirudin
Venlafaxine may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Desirudin
Venlafaxine (Compound) resembles Desvenlafaxine (Compound) and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
|
DB00361
|
DB11569
| 134
| 1,093
|
[
"DDInter1939",
"DDInter1003"
] |
Vinorelbine
|
Ixekizumab
|
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting. A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug.
|
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
|
Moderate
| 1
|
[
[
[
134,
24,
1093
]
],
[
[
134,
63,
1461
],
[
1461,
23,
1093
]
],
[
[
134,
63,
66
],
[
66,
24,
1093
]
],
[
[
134,
24,
496
],
[
496,
24,
1093
]
],
[
[
134,
24,
1367
],
[
1367,
63,
1093
]
],
[
[
134,
64,
1057
],
[
1057,
25,
1093
]
],
[
[
134,
25,
676
],
[
676,
64,
1093
]
],
[
[
134,
25,
1377
],
[
1377,
25,
1093
]
],
[
[
134,
63,
1461
],
[
1461,
62,
66
],
[
66,
24,
1093
]
],
[
[
134,
63,
66
],
[
66,
23,
1114
],
[
1114,
23,
1093
]
]
] |
[
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ixekizumab"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
],
[
"Hepatitis B Vaccine (Recombinant)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
]
],
[
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
]
],
[
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ixekizumab"
]
]
] |
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ixekizumab
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant) and Hepatitis B Vaccine (Recombinant) may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Vinorelbine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ixekizumab
Vinorelbine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Ixekizumab
Vinorelbine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Ixekizumab
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ixekizumab
|
DB00731
|
DB01583
| 1,144
| 624
|
[
"DDInter1269",
"DDInter1075"
] |
Nateglinide
|
Liotrix
|
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may
|
Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal secretion. It is now known that the thyroid gland secretes approximately ten times more T4 than T3 and that 80% of serum T3 is derived from deiodination of T4 in peripheral tissues. Administration of levothyroxine alone is sufficient for maintaining serum T4 and T3 levels in most patients and combination hormone replacement therapy generally offers no therapeutic advantage. In fact, administration of T3 may result in supratherapeutic levels of T3.
|
Moderate
| 1
|
[
[
[
1144,
24,
624
]
],
[
[
1144,
63,
1152
],
[
1152,
1,
624
]
],
[
[
1144,
63,
542
],
[
542,
40,
624
]
],
[
[
1144,
6,
1829
],
[
1829,
45,
624
]
],
[
[
1144,
21,
28936
],
[
28936,
60,
624
]
],
[
[
1144,
63,
417
],
[
417,
23,
624
]
],
[
[
1144,
24,
135
],
[
135,
63,
624
]
],
[
[
1144,
63,
590
],
[
590,
24,
624
]
],
[
[
1144,
24,
959
],
[
959,
24,
624
]
],
[
[
1144,
63,
1152
],
[
1152,
1,
542
],
[
542,
40,
624
]
]
] |
[
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} (Compound) resembles {v} (Compound)",
"Liotrix"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
],
[
"Levothyroxine",
"{u} (Compound) resembles {v} (Compound)",
"Liotrix"
]
],
[
[
"Nateglinide",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
"Liotrix"
]
],
[
[
"Nateglinide",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperhidrosis"
],
[
"Hyperhidrosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Liotrix"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liotrix"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
],
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} (Compound) resembles {v} (Compound)",
"Levothyroxine"
],
[
"Levothyroxine",
"{u} (Compound) resembles {v} (Compound)",
"Liotrix"
]
]
] |
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Liotrix (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine (Compound) resembles Liotrix (Compound)
Nateglinide (Compound) binds ALB (Gene) and ALB (Gene) is bound by Liotrix (Compound)
Nateglinide (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Liotrix (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Liotrix
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide and Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Liotrix
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Liotrix
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Liotrix
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Levothyroxine (Compound) and Levothyroxine (Compound) resembles Liotrix (Compound)
|
DB00280
|
DB01218
| 494
| 1,493
|
[
"DDInter575",
"DDInter852"
] |
Disopyramide
|
Halofantrine
|
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
|
Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.
|
Major
| 2
|
[
[
[
494,
25,
1493
]
],
[
[
494,
6,
8374
],
[
8374,
45,
1493
]
],
[
[
494,
21,
28763
],
[
28763,
60,
1493
]
],
[
[
494,
40,
211
],
[
211,
23,
1493
]
],
[
[
494,
23,
112
],
[
112,
23,
1493
]
],
[
[
494,
24,
770
],
[
770,
24,
1493
]
],
[
[
494,
24,
1017
],
[
1017,
63,
1493
]
],
[
[
494,
1,
573
],
[
573,
63,
1493
]
],
[
[
494,
25,
1213
],
[
1213,
64,
1493
]
],
[
[
494,
25,
79
],
[
79,
25,
1493
]
]
] |
[
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Disopyramide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Halofantrine"
]
],
[
[
"Disopyramide",
"{u} (Compound) causes {v} (Side Effect)",
"Chest pain"
],
[
"Chest pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Halofantrine"
]
],
[
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound)",
"Tolterodine"
],
[
"Tolterodine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Halofantrine"
]
],
[
[
"Disopyramide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Halofantrine"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halofantrine"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halofantrine"
]
],
[
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound)",
"Fesoterodine"
],
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halofantrine"
]
],
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
]
] |
Disopyramide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Halofantrine (Compound)
Disopyramide (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Halofantrine (Compound)
Disopyramide (Compound) resembles Tolterodine (Compound) and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Halofantrine
Disopyramide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Halofantrine
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine
Disopyramide (Compound) resembles Fesoterodine (Compound) and Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine
Disopyramide may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Halofantrine
Disopyramide may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may lead to a major life threatening interaction when taken with Halofantrine
|
DB00800
|
DB01234
| 572
| 1,220
|
[
"DDInter720",
"DDInter513"
] |
Fenoldopam
|
Dexamethasone
|
A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
|
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
|
Moderate
| 1
|
[
[
[
572,
24,
1220
]
],
[
[
572,
63,
870
],
[
870,
1,
1220
]
],
[
[
572,
63,
175
],
[
175,
40,
1220
]
],
[
[
572,
24,
617
],
[
617,
40,
1220
]
],
[
[
572,
21,
28882
],
[
28882,
60,
1220
]
],
[
[
572,
24,
1344
],
[
1344,
63,
1220
]
],
[
[
572,
63,
1648
],
[
1648,
24,
1220
]
],
[
[
572,
24,
1019
],
[
1019,
64,
1220
]
],
[
[
572,
24,
593
],
[
593,
25,
1220
]
],
[
[
572,
63,
870
],
[
870,
1,
175
],
[
175,
40,
1220
]
]
] |
[
[
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Fenoldopam",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
]
],
[
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
]
],
[
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
]
] |
Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamethasone (Compound)
Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Dexamethasone (Compound)
Fenoldopam (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dexamethasone (Compound)
Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may lead to a major life threatening interaction when taken with Dexamethasone
Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Dexamethasone
Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Triamcinolone (Compound) and Triamcinolone (Compound) resembles Dexamethasone (Compound)
|
DB00559
|
DB09122
| 152
| 1,613
|
[
"DDInter223",
"DDInter1409"
] |
Bosentan
|
Peginterferon beta-1a
|
Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.
|
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.
|
Moderate
| 1
|
[
[
[
152,
24,
1613
]
],
[
[
152,
63,
600
],
[
600,
24,
1613
]
],
[
[
152,
62,
168
],
[
168,
24,
1613
]
],
[
[
152,
24,
1274
],
[
1274,
24,
1613
]
],
[
[
152,
25,
263
],
[
263,
24,
1613
]
],
[
[
152,
24,
351
],
[
351,
63,
1613
]
],
[
[
152,
25,
484
],
[
484,
63,
1613
]
],
[
[
152,
25,
1377
],
[
1377,
25,
1613
]
],
[
[
152,
63,
600
],
[
600,
24,
671
],
[
671,
24,
1613
]
],
[
[
152,
62,
168
],
[
168,
24,
671
],
[
671,
24,
1613
]
]
] |
[
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Bosentan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
],
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Bosentan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
]
] |
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Bosentan may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Bosentan may lead to a major life threatening interaction when taken with Axitinib and Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Bosentan may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Bosentan may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Bosentan may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
|
DB00196
|
DB00450
| 600
| 78
|
[
"DDInter743",
"DDInter603"
] |
Fluconazole
|
Droperidol
|
Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.
|
A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593)
|
Major
| 2
|
[
[
[
600,
25,
78
]
],
[
[
600,
25,
1300
],
[
1300,
40,
78
]
],
[
[
600,
25,
1568
],
[
1568,
1,
78
]
],
[
[
600,
21,
28921
],
[
28921,
60,
78
]
],
[
[
600,
23,
112
],
[
112,
62,
78
]
],
[
[
600,
24,
159
],
[
159,
63,
78
]
],
[
[
600,
23,
222
],
[
222,
63,
78
]
],
[
[
600,
24,
971
],
[
971,
64,
78
]
],
[
[
600,
25,
1011
],
[
1011,
64,
78
]
],
[
[
600,
24,
1494
],
[
1494,
25,
78
]
]
] |
[
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Haloperidol"
],
[
"Haloperidol",
"{u} (Compound) resembles {v} (Compound)",
"Droperidol"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pimozide"
],
[
"Pimozide",
"{u} (Compound) resembles {v} (Compound)",
"Droperidol"
]
],
[
[
"Fluconazole",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Droperidol"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Droperidol"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droperidol"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droperidol"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
]
]
] |
Fluconazole may lead to a major life threatening interaction when taken with Haloperidol and Haloperidol (Compound) resembles Droperidol (Compound)
Fluconazole may lead to a major life threatening interaction when taken with Pimozide and Pimozide (Compound) resembles Droperidol (Compound)
Fluconazole (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Droperidol (Compound)
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Droperidol
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Droperidol
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Droperidol
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may lead to a major life threatening interaction when taken with Droperidol
Fluconazole may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Droperidol
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may lead to a major life threatening interaction when taken with Droperidol
|
DB00030
|
DB00692
| 1,685
| 274
|
[
"DDInter934",
"DDInter1448"
] |
Insulin human
|
Phentolamine
|
Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys
|
Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[A261781, A261786] It has several therapeutic uses, including the treatment of hypertensive episodes, prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue anesthesia, and treatment of pharmacologically-induced mydriasis.[L48420, L48415, L48390] Phentolamine is administered intravenously, intramuscularly, submucosally, and topically.
|
Minor
| 0
|
[
[
[
1685,
23,
274
]
],
[
[
1685,
24,
695
],
[
695,
24,
274
]
],
[
[
1685,
24,
1399
],
[
1399,
63,
274
]
],
[
[
1685,
24,
695
],
[
695,
6,
5372
],
[
5372,
45,
274
]
],
[
[
1685,
24,
1399
],
[
1399,
63,
1296
],
[
1296,
62,
274
]
],
[
[
1685,
24,
551
],
[
551,
21,
29118
],
[
29118,
60,
274
]
],
[
[
1685,
24,
1508
],
[
1508,
24,
1296
],
[
1296,
62,
274
]
],
[
[
1685,
24,
675
],
[
675,
40,
11288
],
[
11288,
1,
274
]
],
[
[
1685,
24,
1399
],
[
1399,
63,
1179
],
[
1179,
23,
274
]
],
[
[
1685,
24,
675
],
[
675,
18,
2183
],
[
2183,
57,
274
]
]
] |
[
[
[
"Insulin human",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phentolamine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} (Compound) binds {v} (Gene)",
"ADRA2A"
],
[
"ADRA2A",
"{u} (Gene) is bound by {v} (Compound)",
"Phentolamine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phentolamine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
[
"Phenelzine",
"{u} (Compound) causes {v} (Side Effect)",
"Tachycardia"
],
[
"Tachycardia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Phentolamine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
],
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phentolamine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} (Compound) resembles {v} (Compound)",
"Antazoline"
],
[
"Antazoline",
"{u} (Compound) resembles {v} (Compound)",
"Phentolamine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phentolamine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)",
"Phentolamine"
]
]
] |
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) is bound by Phentolamine (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a minor interaction that can limit clinical effects when taken with Phentolamine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Phentolamine (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine and Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a minor interaction that can limit clinical effects when taken with Phentolamine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Antazoline (Compound) and Antazoline (Compound) resembles Phentolamine (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Phentolamine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Phentolamine (Compound)
|
DB01100
|
DB01156
| 1,568
| 593
|
[
"DDInter1470",
"DDInter252"
] |
Pimozide
|
Bupropion
|
A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403)
|
Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810] Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), or Selective Serotonin Reuptake Inhibitors (SSRIs). While it has comparable effectiveness to typical first-line options for the treatment of depression such as SSRIs,[A178798,A178804] bupropion is a unique option for the treatment of MDD as it lacks any clinically relevant serotonergic effects, typical of other mood medications, or any effects on histamine or adrenaline receptors.[A6399,A178840] Lack of activity at these receptors results in a more tolerable side effect profile; bupropion is less likely to cause sexual side effects, sedation, or weight gain as compared to SSRIs or TCAs, for example.[A178804,A178807] When used as an aid to smoking cessation, bupropion is thought to confer its anti-craving and anti-withdrawal effects by inhibiting dopamine reuptake, which is thought to be involved in the reward pathways associated with nicotine, and through the antagonism of the nicotinic acetylcholinergic receptor.[A178825,A1966,A16508] A Cochrane Review of meta-analyses of available treatment modalities for smoking cessation found that abstinence rates approximately doubled when bupropion was used as compared to placebo, and was found to have similar rates of smoking cessation as [nicotine] replacement therapy (NRT). Bupropion is sometimes used as an add-on agent to first-line treatments of depression such as selective serotonin reuptake inhibitor (SSRI) medications when there is a treatment-failure or only partial response. Bupropion is also used off-label for the management of Attention/Deficit-Hyperactivity Disorder (ADHD) in adults with comorbid bipolar depression to avoid mood destabilization caused by typical stimulant medications used for the treatment of ADHD. When used in combination with [naltrexone] in the marketed product ContraveⓇ for chronic weight management, the two components are thought to have effects on areas of the brain involved in the regulation of food intake. This includes the hypothalamus, which is involved in appetite regulation, and the mesolimbic dopamine circuit, which is involved in reward pathways. Studies have shown that the combined activity of bupropion and [naltrexone] increase the firing rate of hypothalamic pro-opiomelanocortin (POMC) neurons and blockade of opioid receptor-mediated POMC auto-inhibition, which are associated with a reduction in food intake and increased energy expenditure.[L6562,A179038,A179050] The combination of naltrexone and bupropion was shown to result in a statistically significant weight loss, with a mean change in body weight of -6.3% compared to -1.3% for placebo.
|
Major
| 2
|
[
[
[
1568,
25,
593
]
],
[
[
1568,
6,
8374
],
[
8374,
45,
593
]
],
[
[
1568,
18,
4930
],
[
4930,
57,
593
]
],
[
[
1568,
7,
8386
],
[
8386,
57,
593
]
],
[
[
1568,
21,
29087
],
[
29087,
60,
593
]
],
[
[
1568,
64,
752
],
[
752,
23,
593
]
],
[
[
1568,
24,
1532
],
[
1532,
63,
593
]
],
[
[
1568,
25,
1593
],
[
1593,
63,
593
]
],
[
[
1568,
63,
506
],
[
506,
24,
593
]
],
[
[
1568,
64,
322
],
[
322,
24,
593
]
]
] |
[
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Pimozide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bupropion"
]
],
[
[
"Pimozide",
"{u} (Compound) downregulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downregulated by {v} (Compound)",
"Bupropion"
]
],
[
[
"Pimozide",
"{u} (Compound) upregulates {v} (Gene)",
"MTHFD2"
],
[
"MTHFD2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Bupropion"
]
],
[
[
"Pimozide",
"{u} (Compound) causes {v} (Side Effect)",
"Amenorrhoea"
],
[
"Amenorrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bupropion"
]
],
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bupropion"
]
],
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
]
] |
Pimozide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bupropion (Compound)
Pimozide (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Bupropion (Compound)
Pimozide (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Bupropion (Compound)
Pimozide (Compound) causes Amenorrhoea (Side Effect) and Amenorrhoea (Side Effect) is caused by Bupropion (Compound)
Pimozide may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Bupropion
Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Pimozide may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Pimozide may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
|
DB00312
|
DB00451
| 1,023
| 542
|
[
"DDInter1423",
"DDInter1064"
] |
Pentobarbital
|
Levothyroxine
|
A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
|
Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T<sub>4</sub> (tetraiodothyronine or thyroxine) and T<sub>3</sub> (triiodothyronine or ), resulting in diminished down-stream effects of these hormones. Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop such as fatigue, increased heart rate, depression, dry skin and hair, muscle cramps, constipation, weight gain, memory impairment, and poor tolerance to cold temperatures.[F4636,A35722] In response to Thyroid Stimulating Hormone (TSH) release by the pituitary gland, a normally functioning thyroid gland will produce and secrete T<sub>4</sub>, which is then converted through deiodination (by type I or type II 5′-deiodinases) into its active metabolite T<sub>3</sub>. While T<sub>4</sub> is the major product secreted by the thyroid gland, T<sub>3</sub> exerts the majority of the physiological effects of the thyroid hormones; T<sub>4</sub> and T<sub>3</sub> have a relative potency of ~1:4 (T4:T3). T<sub>4</sub> and T<sub>3</sub> act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. As a result, many cardiac functions including heart rate, cardiac output, and systemic vascular resistance are closely linked to thyroid status. Prior to the development of levothyroxine, or desiccated thyroid, used to be the mainstay of treatment for hypothyroidism. However, this is no longer recommended for the majority of patients due to several clinical concerns including limited controlled trials supporting its use. Desiccated thyroid products contain a ratio of T4 to T3 of 4.2:1, which is significantly lower than the 14:1 ratio of secretion by the human thyroid gland. This higher proportion of T3 in desiccated thyroid products can lead to supraphysiologic levels of T3 which may put patients at risk of thyrotoxicosis if thyroid extract therapy is not adjusted according to the serum TSH.[A35722, F4636]
|
Moderate
| 1
|
[
[
[
1023,
24,
542
]
],
[
[
1023,
63,
1152
],
[
1152,
1,
542
]
],
[
[
1023,
6,
8374
],
[
8374,
45,
542
]
],
[
[
1023,
21,
28722
],
[
28722,
60,
542
]
],
[
[
1023,
23,
752
],
[
752,
62,
542
]
],
[
[
1023,
1,
288
],
[
288,
24,
542
]
],
[
[
1023,
24,
1264
],
[
1264,
63,
542
]
],
[
[
1023,
63,
1031
],
[
1031,
24,
542
]
],
[
[
1023,
24,
79
],
[
79,
24,
542
]
],
[
[
1023,
25,
126
],
[
126,
63,
542
]
]
] |
[
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} (Compound) resembles {v} (Compound)",
"Levothyroxine"
]
],
[
[
"Pentobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Levothyroxine"
]
],
[
[
"Pentobarbital",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Levothyroxine"
]
],
[
[
"Pentobarbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levothyroxine"
]
],
[
[
"Pentobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Butalbital"
],
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
]
],
[
[
"Pentobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
]
]
] |
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Levothyroxine (Compound)
Pentobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Levothyroxine (Compound)
Pentobarbital (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Levothyroxine (Compound)
Pentobarbital may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Levothyroxine
Pentobarbital (Compound) resembles Butalbital (Compound) and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine
Pentobarbital may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine
|
DB00960
|
DB06791
| 887
| 1,446
|
[
"DDInter1471",
"DDInter1021"
] |
Pindolol
|
Lanreotide
|
Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the early 1970s. Pindolol was granted FDA approval on 3 September 1982.
|
Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, _Ipsen Pharmaceuticals_ as lanreotide acetate, and marketed as _Somatuline_. It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007.
|
Moderate
| 1
|
[
[
[
887,
24,
1446
]
],
[
[
887,
24,
549
],
[
549,
24,
1446
]
],
[
[
887,
63,
1685
],
[
1685,
24,
1446
]
],
[
[
887,
40,
1121
],
[
1121,
24,
1446
]
],
[
[
887,
1,
88
],
[
88,
24,
1446
]
],
[
[
887,
24,
1344
],
[
1344,
63,
1446
]
],
[
[
887,
24,
549
],
[
549,
24,
154
],
[
154,
63,
1446
]
],
[
[
887,
63,
1685
],
[
1685,
24,
154
],
[
154,
63,
1446
]
],
[
[
887,
40,
1121
],
[
1121,
24,
549
],
[
549,
24,
1446
]
],
[
[
887,
1,
88
],
[
88,
24,
549
],
[
549,
24,
1446
]
]
] |
[
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Bisoprolol"
],
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
],
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
],
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Bisoprolol"
],
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
]
] |
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Pindolol (Compound) resembles Bisoprolol (Compound) and Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Pindolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Pindolol (Compound) resembles Bisoprolol (Compound) and Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Pindolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
|
DB00235
|
DB00261
| 444
| 702
|
[
"DDInter1221",
"DDInter93"
] |
Milrinone
|
Anagrelide
|
Heart failure is a multifactorial condition that affects roughly 1-2% of the adult population. Often the result of long-term myocardial ischemia, cardiomyopathy, or other cardiac insults, heart failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and metabolites, resulting in complex systemic pathologies. Heart failure is underpinned by numerous physiological changes, including alteration in β-adrenergic signalling and cyclic adenosine monophosphate (cAMP) production, which affects the heart's contractile function and cardiac output. Milrinone is a second-generation bipyridine phosphodiesterase (PDE) inhibitor created through chemical modification of [amrinone]. As a PDE-III inhibitor, milrinone results in increased cAMP levels and improves cardiac function and peripheral vasodilation in acute decongested heart failure.[A228338, A11759, A228323, A228333, A228348
|
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.
|
Moderate
| 1
|
[
[
[
444,
24,
702
]
],
[
[
444,
6,
9977
],
[
9977,
45,
702
]
],
[
[
444,
21,
29434
],
[
29434,
60,
702
]
],
[
[
444,
1,
1111
],
[
1111,
63,
702
]
],
[
[
444,
6,
9977
],
[
9977,
45,
1031
],
[
1031,
63,
702
]
],
[
[
444,
21,
29434
],
[
29434,
60,
772
],
[
772,
63,
702
]
],
[
[
444,
21,
28763
],
[
28763,
60,
112
],
[
112,
62,
702
]
],
[
[
444,
21,
29426
],
[
29426,
60,
529
],
[
529,
24,
702
]
],
[
[
444,
21,
28844
],
[
28844,
60,
1213
],
[
1213,
64,
702
]
],
[
[
444,
1,
1111
],
[
1111,
6,
9977
],
[
9977,
45,
702
]
]
] |
[
[
[
"Milrinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
]
],
[
[
"Milrinone",
"{u} (Compound) binds {v} (Gene)",
"PDE3A"
],
[
"PDE3A",
"{u} (Gene) is bound by {v} (Compound)",
"Anagrelide"
]
],
[
[
"Milrinone",
"{u} (Compound) causes {v} (Side Effect)",
"Angina pectoris"
],
[
"Angina pectoris",
"{u} (Side Effect) is caused by {v} (Compound)",
"Anagrelide"
]
],
[
[
"Milrinone",
"{u} (Compound) resembles {v} (Compound)",
"Amrinone"
],
[
"Amrinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
]
],
[
[
"Milrinone",
"{u} (Compound) binds {v} (Gene)",
"PDE3A"
],
[
"PDE3A",
"{u} (Gene) is bound by {v} (Compound)",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
]
],
[
[
"Milrinone",
"{u} (Compound) causes {v} (Side Effect)",
"Angina pectoris"
],
[
"Angina pectoris",
"{u} (Side Effect) is caused by {v} (Compound)",
"Carvedilol"
],
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
]
],
[
[
"Milrinone",
"{u} (Compound) causes {v} (Side Effect)",
"Chest pain"
],
[
"Chest pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Anagrelide"
]
],
[
[
"Milrinone",
"{u} (Compound) causes {v} (Side Effect)",
"Torsade de pointes"
],
[
"Torsade de pointes",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
]
],
[
[
"Milrinone",
"{u} (Compound) causes {v} (Side Effect)",
"Ventricular arrhythmia"
],
[
"Ventricular arrhythmia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
]
],
[
[
"Milrinone",
"{u} (Compound) resembles {v} (Compound)",
"Amrinone"
],
[
"Amrinone",
"{u} (Compound) binds {v} (Gene)",
"PDE3A"
],
[
"PDE3A",
"{u} (Gene) is bound by {v} (Compound)",
"Anagrelide"
]
]
] |
Milrinone (Compound) binds PDE3A (Gene) and PDE3A (Gene) is bound by Anagrelide (Compound)
Milrinone (Compound) causes Angina pectoris (Side Effect) and Angina pectoris (Side Effect) is caused by Anagrelide (Compound)
Milrinone (Compound) resembles Amrinone (Compound) and Amrinone may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide
Milrinone (Compound) binds PDE3A (Gene) and PDE3A (Gene) is bound by Theophylline (Compound) and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide
Milrinone (Compound) causes Angina pectoris (Side Effect) and Angina pectoris (Side Effect) is caused by Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide
Milrinone (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Anagrelide
Milrinone (Compound) causes Torsade de pointes (Side Effect) and Torsade de pointes (Side Effect) is caused by Fluvoxamine (Compound) and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide
Milrinone (Compound) causes Ventricular arrhythmia (Side Effect) and Ventricular arrhythmia (Side Effect) is caused by Dasatinib (Compound) and Dasatinib may lead to a major life threatening interaction when taken with Anagrelide
Milrinone (Compound) resembles Amrinone (Compound) and Amrinone (Compound) binds PDE3A (Gene) and PDE3A (Gene) is bound by Anagrelide (Compound)
|
DB00674
|
DB01176
| 1,516
| 537
|
[
"DDInter802",
"DDInter453"
] |
Galantamine
|
Cyclizine
|
Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as _Galanthus nivalis_. Galantamine was first studied in paralytic and neuropathic conditions, such as myopathies and postpolio paralytic conditions, and for reversal of neuromuscular blockade.[A182993,A201968] Following the discovery of its AChE-inhibiting properties, the cognitive effects of galantamine were studied in a wide variety of psychiatric disorders such as mild cognitive impairment, cognitive impairment in schizophrenia and bipolar disorder, and autism; however, re-development of the drug for Alzheimer’s disease did not commence until the early 1990s due to difficulties in extraction and
|
A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
|
Moderate
| 1
|
[
[
[
1516,
24,
537
]
],
[
[
1516,
24,
1511
],
[
1511,
63,
537
]
],
[
[
1516,
24,
104
],
[
104,
1,
537
]
],
[
[
1516,
63,
13
],
[
13,
24,
537
]
],
[
[
1516,
21,
29058
],
[
29058,
60,
537
]
],
[
[
1516,
24,
1123
],
[
1123,
24,
537
]
],
[
[
1516,
1,
828
],
[
828,
24,
537
]
],
[
[
1516,
24,
1376
],
[
1376,
35,
537
]
],
[
[
1516,
24,
1511
],
[
1511,
40,
11286
],
[
11286,
1,
537
]
],
[
[
1516,
24,
104
],
[
104,
24,
1511
],
[
1511,
63,
537
]
]
] |
[
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Cyclizine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Galantamine",
"{u} (Compound) causes {v} (Side Effect)",
"Hepatitis"
],
[
"Hepatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cyclizine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
],
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Galantamine",
"{u} (Compound) resembles {v} (Compound)",
"Oxycodone"
],
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} (Compound) resembles {v} (Compound)",
"Diphenylpyraline"
],
[
"Diphenylpyraline",
"{u} (Compound) resembles {v} (Compound)",
"Cyclizine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
]
] |
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Cyclizine (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Galantamine (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Cyclizine (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Galantamine (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Cyclizine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate (Compound) resembles Diphenylpyraline (Compound) and Diphenylpyraline (Compound) resembles Cyclizine (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
|
DB00086
|
DB06779
| 1,167
| 365
|
[
"DDInter1712",
"DDInter470"
] |
Streptokinase
|
Dalteparin
|
Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci.
|
Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
|
Major
| 2
|
[
[
[
1167,
25,
365
]
],
[
[
1167,
23,
539
],
[
539,
62,
365
]
],
[
[
1167,
24,
954
],
[
954,
24,
365
]
],
[
[
1167,
24,
1496
],
[
1496,
63,
365
]
],
[
[
1167,
63,
1595
],
[
1595,
24,
365
]
],
[
[
1167,
24,
1018
],
[
1018,
25,
365
]
],
[
[
1167,
25,
256
],
[
256,
25,
365
]
],
[
[
1167,
25,
1468
],
[
1468,
64,
365
]
],
[
[
1167,
64,
1172
],
[
1172,
25,
365
]
],
[
[
1167,
24,
578
],
[
578,
64,
365
]
]
] |
[
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Streptokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dalteparin"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalteparin"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
],
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalteparin"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Collagenase clostridium histolyticum"
],
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalteparin"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
],
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
]
] |
Streptokinase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Dalteparin
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum and Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Dalteparin
Streptokinase may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may lead to a major life threatening interaction when taken with Dalteparin
Streptokinase may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may lead to a major life threatening interaction when taken with Dalteparin
Streptokinase may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Dalteparin
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may lead to a major life threatening interaction when taken with Dalteparin
|
DB00491
|
DB01403
| 127
| 9
|
[
"DDInter1217",
"DDInter1175"
] |
Miglitol
|
Methotrimeprazine
|
Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. Miglitol inhibits alpha-glucosidase, making less sugars available for digestion and reducing postprandial hyperglycemia. Unlike other drugs of the same class, miglitol is not metabolized and the unmetabolized drug is excreted by the kidneys.
|
A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
|
Moderate
| 1
|
[
[
[
127,
24,
9
]
],
[
[
127,
24,
1178
],
[
1178,
40,
9
]
],
[
[
127,
24,
401
],
[
401,
24,
9
]
],
[
[
127,
24,
1630
],
[
1630,
1,
9
]
],
[
[
127,
63,
508
],
[
508,
40,
9
]
],
[
[
127,
21,
28898
],
[
28898,
60,
9
]
],
[
[
127,
63,
417
],
[
417,
23,
9
]
],
[
[
127,
63,
1466
],
[
1466,
24,
9
]
],
[
[
127,
24,
1616
],
[
1616,
63,
9
]
],
[
[
127,
24,
1154
],
[
1154,
64,
9
]
]
] |
[
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Methotrimeprazine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
],
[
"Perphenazine",
"{u} (Compound) resembles {v} (Compound)",
"Methotrimeprazine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Methotrimeprazine"
]
],
[
[
"Miglitol",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methotrimeprazine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
],
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
],
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrimeprazine"
]
]
] |
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Methotrimeprazine (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Methotrimeprazine (Compound)
Miglitol (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Methotrimeprazine (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Methotrimeprazine
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Methotrimeprazine
|
DB00531
|
DB00880
| 450
| 359
|
[
"DDInter456",
"DDInter360"
] |
Cyclophosphamide
|
Chlorothiazide
|
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
|
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)
|
Moderate
| 1
|
[
[
[
450,
24,
359
]
],
[
[
450,
24,
1577
],
[
1577,
1,
359
]
],
[
[
450,
63,
811
],
[
811,
1,
359
]
],
[
[
450,
21,
28784
],
[
28784,
60,
359
]
],
[
[
450,
24,
126
],
[
126,
23,
359
]
],
[
[
450,
63,
590
],
[
590,
24,
359
]
],
[
[
450,
24,
959
],
[
959,
63,
359
]
],
[
[
450,
24,
970
],
[
970,
24,
359
]
],
[
[
450,
24,
1577
],
[
1577,
1,
11764
],
[
11764,
40,
359
]
],
[
[
450,
24,
504
],
[
504,
1,
1577
],
[
1577,
1,
359
]
]
] |
[
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Chlorothiazide"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Chlorothiazide"
]
],
[
[
"Cyclophosphamide",
"{u} (Compound) causes {v} (Side Effect)",
"Thrombocytopenia"
],
[
"Thrombocytopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Chlorothiazide"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
],
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Cyclothiazide"
],
[
"Cyclothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Chlorothiazide"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Chlorothiazide"
]
]
] |
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound)
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Chlorothiazide (Compound)
Cyclophosphamide (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Chlorothiazide (Compound)
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Chlorothiazide
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil and Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide (Compound) resembles Cyclothiazide (Compound) and Cyclothiazide (Compound) resembles Chlorothiazide (Compound)
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Hydroflumethiazide (Compound) and Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound)
|
DB00488
|
DB00495
| 196
| 139
|
[
"DDInter57",
"DDInter1961"
] |
Altretamine
|
Zidovudine
|
An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects.
|
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
|
Moderate
| 1
|
[
[
[
196,
24,
139
]
],
[
[
196,
21,
29209
],
[
29209,
60,
139
]
],
[
[
196,
24,
752
],
[
752,
62,
139
]
],
[
[
196,
24,
810
],
[
810,
63,
139
]
],
[
[
196,
63,
599
],
[
599,
24,
139
]
],
[
[
196,
25,
770
],
[
770,
63,
139
]
],
[
[
196,
25,
1377
],
[
1377,
64,
139
]
],
[
[
196,
64,
581
],
[
581,
25,
139
]
],
[
[
196,
21,
29209
],
[
29209,
60,
231
],
[
231,
40,
139
]
],
[
[
196,
21,
28748
],
[
28748,
60,
387
],
[
387,
62,
139
]
]
] |
[
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
]
],
[
[
"Altretamine",
"{u} (Compound) causes {v} (Side Effect)",
"Anorexia"
],
[
"Anorexia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Zidovudine"
]
],
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zidovudine"
]
],
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
],
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
]
],
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
]
],
[
[
"Altretamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
]
],
[
[
"Altretamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
]
],
[
[
"Altretamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
]
],
[
[
"Altretamine",
"{u} (Compound) causes {v} (Side Effect)",
"Anorexia"
],
[
"Anorexia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Stavudine"
],
[
"Stavudine",
"{u} (Compound) resembles {v} (Compound)",
"Zidovudine"
]
],
[
[
"Altretamine",
"{u} (Compound) causes {v} (Side Effect)",
"Vertigo"
],
[
"Vertigo",
"{u} (Side Effect) is caused by {v} (Compound)",
"Acyclovir"
],
[
"Acyclovir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zidovudine"
]
]
] |
Altretamine (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Zidovudine (Compound)
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Zidovudine
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Altretamine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Altretamine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Zidovudine
Altretamine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Zidovudine
Altretamine (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Stavudine (Compound) and Stavudine (Compound) resembles Zidovudine (Compound)
Altretamine (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Acyclovir (Compound) and Acyclovir may cause a minor interaction that can limit clinical effects when taken with Zidovudine
|
DB00619
|
DB00655
| 1,419
| 559
|
[
"DDInter909",
"DDInter682"
] |
Imatinib
|
Estrone
|
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
|
Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase.
|
Moderate
| 1
|
[
[
[
1419,
24,
559
]
],
[
[
1419,
24,
35
],
[
35,
40,
559
]
],
[
[
1419,
63,
380
],
[
380,
40,
559
]
],
[
[
1419,
24,
1438
],
[
1438,
1,
559
]
],
[
[
1419,
6,
7950
],
[
7950,
45,
559
]
],
[
[
1419,
21,
28703
],
[
28703,
60,
559
]
],
[
[
1419,
63,
752
],
[
752,
23,
559
]
],
[
[
1419,
24,
1264
],
[
1264,
62,
559
]
],
[
[
1419,
24,
167
],
[
167,
63,
559
]
],
[
[
1419,
24,
1573
],
[
1573,
24,
559
]
]
] |
[
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estrone"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
],
[
"Quinestrol",
"{u} (Compound) resembles {v} (Compound)",
"Estrone"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conjugated estrogens"
],
[
"Conjugated estrogens",
"{u} (Compound) resembles {v} (Compound)",
"Estrone"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
],
[
"Estradiol",
"{u} (Compound) resembles {v} (Compound)",
"Estrone"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Estrone"
]
],
[
[
"Imatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Estrone"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Estrone"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Estrone"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estrone"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estrone"
]
]
] |
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and Quinestrol (Compound) resembles Estrone (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens (Compound) resembles Estrone (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Estradiol and Estradiol (Compound) resembles Estrone (Compound)
Imatinib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Estrone (Compound)
Imatinib (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Estrone (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Estrone
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Estrone
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Estrone
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Estrone
|
DB00431
|
DB00902
| 1,503
| 104
|
[
"DDInter1072",
"DDInter1168"
] |
Lindane
|
Methdilazine
|
An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical treatment of pediculosis capitis (head lice), pediculosis pubis (pubic lice), or scabies in patients greater than two years of age who cannot tolerate or have failed first-line treatment. Lindane is still allowed for pharmaceutical use until 2015.
|
Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus.
|
Moderate
| 1
|
[
[
[
1503,
24,
104
]
],
[
[
1503,
24,
820
],
[
820,
1,
104
]
],
[
[
1503,
63,
508
],
[
508,
1,
104
]
],
[
[
1503,
24,
401
],
[
401,
63,
104
]
],
[
[
1503,
63,
695
],
[
695,
24,
104
]
],
[
[
1503,
24,
1454
],
[
1454,
24,
104
]
],
[
[
1503,
24,
675
],
[
675,
25,
104
]
],
[
[
1503,
64,
534
],
[
534,
25,
104
]
],
[
[
1503,
25,
593
],
[
593,
64,
104
]
],
[
[
1503,
24,
1311
],
[
1311,
64,
104
]
]
] |
[
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sufentanil"
],
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methdilazine"
]
],
[
[
"Lindane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methdilazine"
]
],
[
[
"Lindane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methdilazine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methdilazine"
]
]
] |
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Methdilazine (Compound)
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Sufentanil and Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Methdilazine
Lindane may lead to a major life threatening interaction when taken with Tramadol and Tramadol may lead to a major life threatening interaction when taken with Methdilazine
Lindane may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Methdilazine
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may lead to a major life threatening interaction when taken with Methdilazine
|
DB00894
|
DB06404
| 1,581
| 1,514
|
[
"DDInter1774",
"DDInter869"
] |
Testolactone
|
Human C1-esterase inhibitor
|
An antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer.
|
C1 Esterase Inhibitor (Human) is composed of purified endogenous complement component-1 esterase inhibitor (hC1INH) isolated from human plasma. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways.[L16586, L16606] This drug is indicated for prophylaxis and treatment of Hereditary Angioedema (HAE), a human genetic disorder caused by a shortage of C1 inhibitor activity that results in an overreaction of the immune system. The disease is characterized by acute attacks of painful, and in some cases, fatal swelling of several soft tissues or edema, which may last up to five days when untreated.[L16586, L16606]
|
Moderate
| 1
|
[
[
[
1581,
24,
1514
]
],
[
[
1581,
1,
984
],
[
984,
24,
1514
]
],
[
[
1581,
40,
559
],
[
559,
24,
1514
]
],
[
[
1581,
1,
1546
],
[
1546,
63,
1514
]
],
[
[
1581,
25,
350
],
[
350,
64,
1514
]
],
[
[
1581,
1,
984
],
[
984,
40,
35
],
[
35,
24,
1514
]
],
[
[
1581,
40,
559
],
[
559,
40,
1438
],
[
1438,
24,
1514
]
],
[
[
1581,
1,
1546
],
[
1546,
1,
984
],
[
984,
24,
1514
]
],
[
[
1581,
24,
687
],
[
687,
63,
1423
],
[
1423,
24,
1514
]
],
[
[
1581,
25,
350
],
[
350,
64,
1423
],
[
1423,
24,
1514
]
]
] |
[
[
[
"Testolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human C1-esterase inhibitor"
]
],
[
[
"Testolactone",
"{u} (Compound) resembles {v} (Compound)",
"Danazol"
],
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human C1-esterase inhibitor"
]
],
[
[
"Testolactone",
"{u} (Compound) resembles {v} (Compound)",
"Estrone"
],
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human C1-esterase inhibitor"
]
],
[
[
"Testolactone",
"{u} (Compound) resembles {v} (Compound)",
"Methyltestosterone"
],
[
"Methyltestosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human C1-esterase inhibitor"
]
],
[
[
"Testolactone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Human C1-esterase inhibitor"
]
],
[
[
"Testolactone",
"{u} (Compound) resembles {v} (Compound)",
"Danazol"
],
[
"Danazol",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
],
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human C1-esterase inhibitor"
]
],
[
[
"Testolactone",
"{u} (Compound) resembles {v} (Compound)",
"Estrone"
],
[
"Estrone",
"{u} (Compound) resembles {v} (Compound)",
"Estradiol"
],
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human C1-esterase inhibitor"
]
],
[
[
"Testolactone",
"{u} (Compound) resembles {v} (Compound)",
"Methyltestosterone"
],
[
"Methyltestosterone",
"{u} (Compound) resembles {v} (Compound)",
"Danazol"
],
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human C1-esterase inhibitor"
]
],
[
[
"Testolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conestat alfa"
],
[
"Conestat alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ospemifene"
],
[
"Ospemifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human C1-esterase inhibitor"
]
],
[
[
"Testolactone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ospemifene"
],
[
"Ospemifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human C1-esterase inhibitor"
]
]
] |
Testolactone (Compound) resembles Danazol (Compound) and Danazol may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor
Testolactone (Compound) resembles Estrone (Compound) and Estrone may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor
Testolactone (Compound) resembles Methyltestosterone (Compound) and Methyltestosterone may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor
Testolactone may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may lead to a major life threatening interaction when taken with Human C1-esterase inhibitor
Testolactone (Compound) resembles Danazol (Compound) and Danazol (Compound) resembles Quinestrol (Compound) and Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor
Testolactone (Compound) resembles Estrone (Compound) and Estrone (Compound) resembles Estradiol (Compound) and Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor
Testolactone (Compound) resembles Methyltestosterone (Compound) and Methyltestosterone (Compound) resembles Danazol (Compound) and Danazol may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor
Testolactone may cause a moderate interaction that could exacerbate diseases when taken with Conestat alfa and Conestat alfa may cause a moderate interaction that could exacerbate diseases when taken with Ospemifene and Ospemifene may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor
Testolactone may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may lead to a major life threatening interaction when taken with Ospemifene and Ospemifene may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor
|
DB00363
|
DB00366
| 695
| 1,594
|
[
"DDInter419",
"DDInter600"
] |
Clozapine
|
Doxylamine
|
Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia. However, its promiscuity toward the muscarinic and adrenergic receptors can result in other side effects, notably gastrointestinal hypomotility and orthostatic hypotension. [L905,A215552]. Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.[A256713,A256718] However, continued evidence of its effectiveness led to clozapine's eventual reintroduction, although
|
Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism.
|
Moderate
| 1
|
[
[
[
695,
24,
1594
]
],
[
[
695,
25,
11
],
[
11,
1,
1594
]
],
[
[
695,
24,
662
],
[
662,
63,
1594
]
],
[
[
695,
25,
1264
],
[
1264,
63,
1594
]
],
[
[
695,
6,
10104
],
[
10104,
45,
1594
]
],
[
[
695,
1,
902
],
[
902,
24,
1594
]
],
[
[
695,
40,
1565
],
[
1565,
63,
1594
]
],
[
[
695,
1,
623
],
[
623,
63,
1594
]
],
[
[
695,
35,
13
],
[
13,
63,
1594
]
],
[
[
695,
63,
1089
],
[
1089,
24,
1594
]
]
] |
[
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound)",
"Doxylamine"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
]
],
[
[
"Clozapine",
"{u} (Compound) binds {v} (Gene)",
"HRH1"
],
[
"HRH1",
"{u} (Gene) is bound by {v} (Compound)",
"Doxylamine"
]
],
[
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound)",
"Clobazam"
],
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
]
],
[
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound)",
"Clonazepam"
],
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
]
],
[
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
]
],
[
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipratropium"
],
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
]
]
] |
Clozapine may lead to a major life threatening interaction when taken with Toremifene and Toremifene (Compound) resembles Doxylamine (Compound)
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine
Clozapine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine
Clozapine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Doxylamine (Compound)
Clozapine (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine
Clozapine (Compound) resembles Clonazepam (Compound) and Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine
Clozapine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine
Clozapine (Compound) resembles Cyproheptadine (Compound) and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Ipratropium and Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine
|
DB00618
|
DB01021
| 1,572
| 674
|
[
"DDInter498",
"DDInter1861"
] |
Demeclocycline
|
Trichlormethiazide
|
A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.
|
A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)
|
Minor
| 0
|
[
[
[
1572,
23,
674
]
],
[
[
1572,
62,
1014
],
[
1014,
40,
674
]
],
[
[
1572,
23,
178
],
[
178,
1,
674
]
],
[
[
1572,
23,
359
],
[
359,
40,
674
]
],
[
[
1572,
40,
964
],
[
964,
23,
674
]
],
[
[
1572,
1,
1669
],
[
1669,
23,
674
]
],
[
[
1572,
24,
126
],
[
126,
23,
674
]
],
[
[
1572,
24,
1296
],
[
1296,
63,
674
]
],
[
[
1572,
63,
176
],
[
176,
24,
674
]
],
[
[
1572,
62,
1014
],
[
1014,
40,
178
],
[
178,
1,
674
]
]
] |
[
[
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
]
],
[
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Polythiazide"
],
[
"Polythiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
]
],
[
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
]
],
[
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
],
[
"Minocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Polythiazide"
],
[
"Polythiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
]
]
] |
Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Benzthiazide and Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Polythiazide and Polythiazide (Compound) resembles Trichlormethiazide (Compound)
Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Trichlormethiazide (Compound)
Demeclocycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a minor interaction that can limit clinical effects when taken with Trichlormethiazide
Demeclocycline (Compound) resembles Minocycline (Compound) and Minocycline may cause a minor interaction that can limit clinical effects when taken with Trichlormethiazide
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Trichlormethiazide
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide
Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Benzthiazide and Benzthiazide (Compound) resembles Polythiazide (Compound) and Polythiazide (Compound) resembles Trichlormethiazide (Compound)
|
DB04845
|
DB13179
| 309
| 68
|
[
"DDInter1001",
"DDInter1882"
] |
Ixabepilone
|
Troleandomycin
|
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation.
|
A macrolide antibiotic that is similar to erythromycin.
|
Moderate
| 1
|
[
[
[
309,
24,
68
]
],
[
[
309,
63,
1101
],
[
1101,
23,
68
]
],
[
[
309,
63,
973
],
[
973,
24,
68
]
],
[
[
309,
24,
710
],
[
710,
24,
68
]
],
[
[
309,
24,
1593
],
[
1593,
25,
68
]
],
[
[
309,
63,
134
],
[
134,
25,
68
]
],
[
[
309,
25,
976
],
[
976,
25,
68
]
],
[
[
309,
24,
159
],
[
159,
64,
68
]
],
[
[
309,
25,
676
],
[
676,
64,
68
]
],
[
[
309,
64,
1377
],
[
1377,
25,
68
]
]
] |
[
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Troleandomycin"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
],
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Ixabepilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Ixabepilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Ixabepilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
]
] |
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Troleandomycin
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may lead to a major life threatening interaction when taken with Troleandomycin
Ixabepilone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Troleandomycin
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may lead to a major life threatening interaction when taken with Troleandomycin
Ixabepilone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Troleandomycin
Ixabepilone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Troleandomycin
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.